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1 Chemistry of tetrahydrofuran amino acids – a short introduction 
 
This chapter provides to the reader a comprehensive overview about the chemistry of the amino acid 
3-amino-2-(4-bromophenyl)tetrahydrofuran-3-carboxylic acid, which is one representative from the 
group of tetrahydrofuran amino acids. 
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1.1 3-Amino-2-(4-bromophenyl)tetrahydrofuran-3-carboxylic acid  
Preparation and properties. The four step synthesis of the cyclic unnatural amino acid 3-amino-2-
(4-bromophenyl)tetrahydrofuran-3-carboxylic acid was reported the first time by König et al. in 
2007.1 The synthesis illustrated in Scheme 1, starts from cheap and commercial available racemic 
methionine rac-1 with N-Boc protection, subsequent protection of the carboxylic group via Steglich-
type esterification and alkylation of the side chain using methyl iodide obtaining sulfonium salt rac-2. 
The crucial step of the reaction sequence is initiated by treatment with KOH to abstract the acidic 
proton in α-position generating an ester enolate. This reacts with 4-bromobenzaldehyde in an aldol-
type reaction, which is followed by an intramolecular nucleophilic substitution reaction employing 
dimethylsulfide as leaving group to build up the tetrahydrofuran amino acid rac-4. 
 
Scheme 1. Synthetic pathway towards unnatural tetrahydrofuran amino acid rac-4 obtained as racemic mixture. 
Reaction conditions: (a) Boc2O, NaOH, 1,4-dioxane/water, RT, 3 h. (b) tBuOH, DCC, DMAP, DCM, RT, 12 h. (c) MeI, 
in the dark, RT, 3 d. (d) KOH, dry MeCN, -6 °C, 2-4 h. 
During the reaction two new stereocenters are formed, leading to in total 4 possible stereoisomers. 
The reaction proceeds with a broad range of aromatic aldehydes, e.g. 4-nitrobenzaldehyde, 4-
methoxybenzaldehyde, benzaldehyde, 4-methylbenzaldehyde, 4-cyanobenzaldehyde, 3-
bromobenzaldyde among others in a highly diastereoselective manner (trans/cis ratio up to 97:3) 
with moderate to good yields (35-78%) depending on the aldehyde used. Best results were obtained 
with aldehyde 3, giving 78% yield and a trans-selectivity of 97:3. Figure 1 shows the proposed 
reaction mechanism and a comparison of the formation of the trans- and cis- isomers. The high 
sterical demanding tBu-ester leads to the preferred formation of trans-isomers and high 
diastereoselectivity. 
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Figure 1. Proposed reaction mechanism for the formation of Cα-tetrasubstituted tetrahydrofuran amino acids.  
Incorporated in small peptides, interesting properties of compound rac-4 were revealed as this class 
of compounds is able to stabilize secondary structures in short peptides. Therefore the R,S,S-isomer 
of Boc-TAA-Ala-NHBn dipeptide adopts a β-turn type I conformation, whereas the S,R,R-isomer does 
not. The elongated R,S,S-isomer of the Ac-Gly-TAA-Ala-NHBn tripeptide showed in the solid state as 
well as in solution a conformation of two consecutive β-turn type III structures, which are stabilized 
by i+3 -> i intramolecular hydrogen bonds (Figure 2). 
 
Figure 2. Structure (left) and X-ray diffraction analysis (center) of Ac-Gly-(R,S)-TAA-(S)-Ala-NHBn, which 
exhibits two consecutive β-turns. They are each stabilized by an intramolecular i+3 -> i hydrogen bond (dashed 
lines), where only amide hydrogen atoms are drawn. The backbone structure of the tripeptide is shown at the 
right side. (Graphics are depicted from literature: Maity, P. PhD Thesis, Universität Regensburg, Regensburg, 
2008). 
Protecting group strategy. First investigations focused on the optimization of the protecting group 
strategy since the combination of Boc-/tBu-ester is not fully orthogonal in the reported synthesis. On 
the one hand, the selective removal of the Boc-group in the presence of the tBu-ester using HCl 
saturated diethyl ether was feasible. But on the other hand, there was no way to cleave the tBu-ester 
and at the same time leaving the Boc-group unharmed. To obtain the N-terminally protected amino 
acid rac-7 it was necessary to remove both groups followed by the reprotection of the amine. This 
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procedure gave rac-7, which is the most interesting building block for peptide syntheses in a 
maximum yield of only 50-60% (Scheme 2). 
 
Scheme 2. Deprotection of rac-4. Reaction conditions: (a) HCl sat. Et2O, DCM, RT, 3 h. (b) 6M HCl, MeOH, reflux, 8 
h. (c) Boc2O, 1.25M aq. NaOH, 1,4-dioxane, 0 °C, 3.5 h. 
In scheme 3, a comparison between Boc-/tBu-ester strategy and the two alternative approaches Boc-
/Bn-ester2 and Cbz-/tBu-ester3,4 is shown. These strategies were examined in detail as they are each 
fully orthogonal protection groups and in addition stable to the strongly basic conditions, which were 
needed during the key step of the tetrahydrofuran amino acid synthesis. 
 
Scheme 3. Comparison of different protection group strategies in the synthesis of tetrahydrofuran amino acids. 
Reaction conditions: (a) KOH (or CsOH), dry MeCN, -6 °C, 2-6 h. 
The overall yields, which are given in brackets for the three step synthesis of the sulfonium salts 
were, still in a comparable range. Moreover the high diastereoselective character (trans/cis = 97:3) of 
the original reaction was retained in both cases and the desired products were formed as racemic 
mixture of the trans-isomers. Unfortunately the yields of the cyclization dropped drastically whereby 
these alternative protection group strategies became quite unattractive indicated also by the 4-step 
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overall yields. In addition some problems during the deprotection occurred: The cleavage of the Cbz-
group via palladium on charcoal catalyzed hydrogenation reaction was accompanied by a ten-time 
faster unwanted reduction of the bromoarene substituent. This site reaction was also partly observed 
during the reductive deprotection of the Bn-ester. Saponification of the Bn-ester with KOH in boiling 
ethanol for 24 h achieved the free acid in poor 24% yield. A third attempt to remove the Bn-group 
using a flavine-mediated photocatalytic reduction5 in MeCN/H2O showed no conversion at all. Finally 
it must be admitted that the combination Boc-/tBu-ester is in spite of the partial restriction the best 
protection group strategy available so far. 
Enantioselective reaction pathway. The second problem of the reported synthesis which needed to 
be investigated more precisely concerned the enantioselective differentiation of the two trans-
isomers representing the major product. Therefore three different approaches were examined in 
detail: chiral menthol ester (Scheme 4),4,6 chiral auxiliary (Scheme 5)7 and the implementation of 
chiral phase transfer catalysts (Figure 3, Scheme 6).8 
In the first attempt, the tBu-ester was replaced by a chiral ester employing (-)menthol during 
esterification, which finally lead to the sulfonium salt derivative 8. The cyclisation reaction with 3 
delivered the trans-product in good yield (69%) and high diastereoselectivity but no 
enantioselectivity was observed and the products 9a and 9b were obtained again as 1:1 mixture. 
Since the two trans-isomers are now no longer enantiomers, but diastereomers, they could be 
separated by standard column chromatography for the first time. The deprotection of the Boc-group 
was easy possible using HCl-saturated diethyl ether whereas the deprotection of the ester group 
needed some more efforts. Finally cleavage with KOH in water/methanol under microwave 
irradiation gave the free acid in acceptable 55% yield.  
 
Scheme 4. Cyclisation reaction analogous to reported procedure using menthol ester derivative 8 to obtain the 
two trans-isomers of Boc-TAA-Omenthol 9a and 9b (1:1). Reaction conditions: (a) KOH, dry MeCN, -6 °C, 4-7 h. 
As a second alternative, the chiral auxiliary (S)-4-isopropyloxazolidin-2-one was used. This was 
reacted with Boc-(S)-Met-OH applying NEt3 and pivaloyl chloride to end up with compound 10. The 
possibility to form a chelat complex with cations can fix the conformation of the ester during 
cyclisation and may induce an access of one enantiomer. Unfortunately the reaction delivered only 
traces of the desired product 11. Modifications of the reaction conditions, like increased reaction 
times up to 24 h, different base (LDA) or different solvent (THF) were also not successful. 
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Scheme 5. Cyclisation reaction performed with sulfonium salt derivative 10 carrying the chiral auxiliary (S)-4-
isopropyloxazolidin-2-one. Reaction conditions: (a) KOH, dry MeCN, -6 °C, 6-24 h or LDA, THF, -78 °C, 6-24 h. 
In the last approach an attempt was made to prepare the substrates rac-2 and 3 of the original 
reaction, using toluene as non-polar solvent and compounds 12-14 (figure 3) as chiral catalysts in a 
phase-transfer reaction.  
 
Figure 3. Chiral phase transfer catalyst 12-14. 
The key-step reaction was carried out in each case with 25 mol% of catalyst. The reaction 
temperature was first kept at -5 °C for 6 h and then allowed to warm up to room temperature for 
additional 12 h. Surprisingly all reactions didn’t lead to the expected tetrahydrofuran amino acid but 
in all cases major amounts of cyclopropan amino acid 15 and elimination product rac-16 were 
formed. Compound 15 is obtained through intramolecular cyclisation of rac-2 when not enough 
aldehyde 3 is present. 
 
Scheme 6. Cyclisation reaction between rac-2 and 3 under phase transfer catalysis with chiral catalysts. 
Reaction conditions: (a) Compound 12 (25 mol%), KOH, toluene, -5 °C for 6 h to RT, 18 h. (b) Compound 13 (25 
mol%), KOH, MeCN, -5 °C for 6 h to RT, 18 h. (c) Compound 14 (25 mol%), KOH, toluene, -5 °C for 6 h to RT, 18 h. 
In summary the menthol ester method delivered at least separable diastereomers whereas the chiral 
auxiliary (S)-4-isopropyloxazolidin-2-one and the chiral phase transfer catalysts failed completely. 
An enhancement of a single enantiomer could not be observed in all three cases. 
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Aliphatic side chains. Since the reaction performed well with a broad scope of aromatic aldehydes, a 
series of aliphatic aldehydes was tested to extend the range of available side chains at the second 
stereocenter.9 In contrast to aromatic aldehydes, aliphatic ones are able to undergo undesired aldol 
side reactions under the strong basic conditions. Therefore pivalaldehyde 17a, which has no 
hydrogen atom in α-position was tested first, but unfortunately no product was obtained. Then n-
butyraldehyde 17e was used, giving 16% of corresponding product 18e. Optimization of the reaction 
conditions showed that CsOH is the best base for aliphatic aldehyde whereas KOH was the best choice 
for aromatic ones. Afterwards some more aldehydes were screened: 2-phenylpropanal 17b, 
isobutyraldehyde 17c, 3-methylbutanl 17d, acetaldehyde 17f or methacrylaldehyde 17g. In 
summary the target cyclic amino acids with aliphatic side chain were obtained in low to moderate 
yields and sometimes good diastereoselectivity (Scheme 7). But in general the selectivity was lower 
than in the case of aromatic aldehydes. 
 
Scheme 7. Cyclisation reaction with various aliphatic aldehydes receiving tetrahydrofuran amino acids. Reaction 
conditions: (a) CsOH, dry MeCN, -6 °C, 4-7 h. 
Right- and left-handed helical peptides.10 Cα-tetrasubstituted α-amino acids like the 
tetrahydrofuran amino acid rac-4 are interesting compounds to rigidify peptide backbones or to 
prepare peptides with defined secondary structures. The turn inducing properties of one 
stereoisomer, which were discovered in the first investigations suggest extending the investigations 
regarding the conformation of TAA containing peptides. Compound rac-4 was used to prepare a 
small library of in total 13 different peptides covering di-, tetra-, hexa- and octapeptides with 
alternating sequences of TAA rac-4 and (S)- or (R)-valine (scheme 8). The structures were 
characterized by X-ray diffraction analysis in the solid state and NMR and circular dichroism 
spectroscopy in solution. The measurements proved that all-S-backbone-configured peptides 20b 
and 20c (SS)2-3 form right-handed 310-helices, while the all-R-configured peptides 22b, 22c and 22d 
(RR)2-4 form left-handed 310-helices in the solid state and solution. In figure 4, the crystal structure of 
peptide 22d is exemplary compared to an α-helix indicating close proximity of corresponding 
residues. Thus rac-4 is applicable for the synthesis of short peptidomimetics with stable secondary 
structures in solution.  
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Scheme 8. Overview about TAA-containing isomeric di-, tetra- hexa- and octapeptides which were synthesized 
and their conformation investigated in detail.  
 
Figure 4. Comparison between the crystal structure of octapeptide 22d (red ribbon, top) and of an ideal α-helix 
(green ribbon, bottom, side chains exemplary indicated by alanine residues). The i, i+3, i+6 residues of 22d are 
in close proximity to the i, i+1 and i+7 residues of the natural α-helical peptide, which make them suitable as 
scaffolds and peptidomimetics (Graphic is depicted from literature: Grauer, A. PhD Thesis, Universität 
Regensburg, Regensburg, 2009). 
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Cyclopeptides. The bromoarene substituent of compound rac-4 enabled further synthetic side chain 
modifications by transition metal-catalyzed reactions, which were examined in an additional study.11 
At first stage the bromo substituent was replaced by a broad range of aliphatic and aromatic amines, 
which was mediated by a homogeneous copper(I) catalyzed N-arylation reaction. After optimization 
of the reaction conditions intramolecular N-arylation reactions were performed to build up cyclic 
peptides like compound 24, but unfortunately only small amounts were obtained. In contrast 
palladium(0) catalyzed O-arylation reaction delivered peptides 26a and 26b in an enantiomerically 
pure form in reasonable yields of 40%, respectively 19%.  
 
Scheme 9. Application of metal-catalyzed reactions like N-arylation with Cu(I) (top) or O-arylation by Pd(0) 
(bottom) for the synthesis of TAA-containing cyclic peptide mimics 24 or 26a,b.  
Conformational study. Based on the results of the previous synthesized (TAA-Val)n (n = 1-4) 
peptides, which adopted 310-helical right- or left-handed structures, it was interesting to clarify in an 
additional conformational study if a single TAA building block is sufficient to induce helical structures 
in short peptides.12 As target peptide sequence -Arg-Lys-Trp-Gln-Lys-Thr-Gly-His-Ala-Val- which 
represents the active side of smooth muscle myosin light chain kinase (smMLCK) was chosen. 
Advantages of this choice are, that smMLCK is a well-known protein, the binding side has an α-helical 
structures and the binding amino acids are also known. Furthermore it binds to Calmodulin, which is 
also well-known and allows examining the synthesized peptide derivative in a binding assay for 
biological activity. Peptides 27a and 28a bearing the turn inducing TAA-building block at the end 
were synthesized. For comparison also the diastereomers 27b and 28b containing S,R-TAA, which 
does not introduce turns into the structure as well as the peptide Gly-His-Ala-Val were prepared. 
Investigations using NMR-techniques and circular dichroism spectroscopy revealed that the peptide 
Gly-His-Ala-Val is too short to adopt a helical structure. So it was excluded that a helical structure is 
already present in the peptide itself and not due to the influence of the TAA-building block. The 
results for 27b and 28b showed as expected also no defined helical structure. The spectroscopic 
measurements of peptides 27a and 27b showed similar results like in the case of 27b and 28b. This, 
proved that no helical structures either 310-helic or α-helic was present. In consequence it was 
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concluded that the induced turn at the beginning of the peptide is not determining the conformation 
of the subsequent peptide chain. 
 
Figure 5. Synthesized peptide 27a,b and 28a,b in this study.  
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2 Pyrene labeled Cα-tetrasubstituted α-amino acids as building blocks 
for fluorescent peptidomimetics 
 
In this chapter the synthesis of pyrene and carboxyfluorescein labeled Cα tetrasubstituted amino 
acids (TAAs) is described. They can be incorporated into peptides to rigidify the structure and at the 
same time introducing a fluorescent label. The fluorescent dye can be coupled to the TAA before or 
after its incorporation into a peptide sequence using a Suzuki-type C-C bond formation. Thus these 
building blocks combine two properties which are often of high interest in the preparation of peptide 
analogues. 
 
 
 
 
 
 
 
 
 
All compounds which are described in this chapter were synthesized by Michael Dobmeier with the 
following exceptions: Compounds rac-3 and 12a were prepared by Prantik Maity and compounds 
16a/16b were synthesized by Muruganantham Rajendran. Prantik Maity contributed the crystal 
structures for compounds rac-3 and 18a/18b. Michael Dobmeier did all UV/Vis and fluorescence 
measurements.  
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2.1 Introduction 
The biological activity of peptides and proteins is based on their conformation which is related to the 
secondary structures of the amino acid sequence.1-3 In this context the major drawback of small 
natural peptides is the conformational flexibility as well as the biological and chemical instability, 
which may hamper the investigation of biological processes or to perform structural studies. 
Therefore the rational design and synthesis of peptides and peptidomimetics4,5 with defined 
structural properties6,7 gained much attention by chemists and biologists in the recent past. To 
stabilize or mimic the conformation of peptides many different approaches exist.8 One very 
successful strategy is the disubstitution in α-position of amino acids9 resulting in a conformational 
constrain, which enables this class of Cα-tetrasubstituted α-amino acids10-14 (T  s) to induce stable β-
turn-15 and helical structures.16-18 Our group recently reported the synthesis of the Cα-
tetrasubstituted tetrahydrofuran amino acid rac-4 with a broad scope of aromatic side chains. As 
part of a peptide sequence they initiate two consecutive β-turns and thus leading to stable secondary 
structure in small peptides.19 Further we described their use in the preparation of stable right- and 
left-handed peptide helices,20 the synthesis of cyclopeptides21 and the synthesis of derivatives with 
aliphatic side chains.22 One of the most powerful and versatile tool for the analysis of peptide and 
protein conformations, visualization of biopolymers23-25 and studies on intracellular processes26 as 
well as intermolecular interactions27-30 is emission spectroscopy. Since only two of the proteinogenic 
amino acids are fluorescent (Trp and Tyr), it is often necessary to attach emitting dyes via side chain 
functionalities to peptide sequences,31,32 e.g. the attachment of 1-vinylpyrrole-2-carbaldeyhdes to the 
ε-amino group of lysine residues by formation of Schiff bases.33 However, side chain functionalities 
are responsible for many molecular interactions in proteins and amino acid labeling may alter or 
prohibit such interactions. Therefore many synthetic fluorescent amino acids have been developed.34-
38 Some representative examples are depicted in Figure 1 including 3-[2-(8-quinolinyl)benzoxazol-5-
yl]alanine derivatives (Fig. 1, a),39 phthalimide based amino acids (Fig. 1, b),40 different substituted 
coumaryl analogues (Fig. 1, c)41 or acridin-9(10H)-one moieties (Fig. 1, d).42 Suhartono et al. 
described the linkage of pyrene and other aromatics by Pd-catalyzed Heck-reaction to β,γ-
unsaturated and protected amino acids, which were obtained via known side chain transformation of 
methionine (Fig. 1, e).43 Finally an example of an anthracene-based bis-armed amino acid is shown 
(Fig. 1, f).44 Transition metal-catalyzed reactions, like Suzuki-,45 Heck-46 or Sonogashira-47 couplings 
are well-established in organic chemistry and highly interesting for the modification of peptides, 
proteins and other biomolecules since they are usually regarded as bio-orthogonal reactions. In 
consequence new catalysts or ligands for mild reaction conditions in aqueous buffered solution at 
room temperature were developed in the last two decades making organopalladium reactions 
compatible to the thermo sensitive and hydrophilic nature of peptides and proteins.48-51 Today 4-
iodo-phenylalanine is frequently used, which can be incorporated into target peptides and proteins 
by solution phase chemistry, solid phase peptide synthesis or through genetically encoding.52 
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Figure 1. Structures of selected synthetic fluorescent amino acids reported in literature. 
We now report several synthetic unnatural TAAs derived from rac-4 bearing fluorescent dyes such as 
pyrene or carboxyfluorescein moieties. Moreover, we show the incorporation of a fluorescent TAA 
building block into a short peptide and the post-functionalization of its bromoarene moiety by a 
pyrene substituent in the peptide via metal-catalyzed bond formation. These amino acids favorably 
combine two properties: They stabilize a secondary peptide structure in solution and show 
interesting absorption and emission in the visible part of the spectrum. 
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2.2  Results and Discussion 
2.2.1  Synthesis of fluorescent TAA building blocks 
The reported synthesis of the TAA rac-4 starts from commercial available methionine with N-Boc 
protection followed by esterification with tert-butanol and finally methylation of the side-chain by 
treatment with methyl iodide to obtain compound rac-1. The key step of the reaction sequence 
consists of an aldol-type reaction of the methionine-derived sulfonium salt rac-1 with an aromatic 
aldehyde and subsequently a cyclization through an intermolecular SN2 reaction. Therefore a first 
derivative rac-3 containing a fluorescent pyrene moiety was prepared by reacting pyrene aldehyde 
instead of 4-bromobenzaldehyde with the sulfonium salt rac-1 under basic conditions in dry 
acetonitrile according to the known procedure (Scheme 1).19 
 
Scheme 1. Synthesis of modified TAA rac-3. Reaction conditions: (a) KOH, MeCN, 0 °C, 2-4 h. 
The compound rac-3 was obtained in a moderate yield of 56%, which is significantly lower than in 
the case of rac-4 (78%) and with a diastereoselectivity of 20:1 (trans/cis), being also slightly worse 
compared to 97:3 (trans/cis) for rac-4. A possible explanation can be the increased steric demand of 
the pyrene moiety directly attached to the tetrahydrofuran ring. To avoid such decrease in yield and 
selectivity the fluorescent moiety was attached via a different strategy using a well-established Pd-
catalyzed Suzuki coupling45 of 1-pyrenyl boronic acid 5 to the brominated substituent of the 
previously reported compound  rac-4 (Scheme 2). The reaction was carried out in a mixture of DME 
and water (1:1), in the presence of K2CO3 as base and afforded compound rac-6 as a fluorescent 
derivate in a yield of 63%. 
 
Scheme 2. Suzuki reaction of TAA rac-4 with 1-pyrenyl boronic acid 5. Reaction conditions: (a) Pd(PPh3)4, K2CO3, 
DME/H2O (1:1), 80 °C, 24 h.  
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In a third attempt a different dye should be connected to illustrate the scope of the concept. For the 
introduction of a carboxyfluorescein moiety we used a copper(I)-catalyzed N-arylation53 to attach 
ethylene diamine as a linker group to rac-4, ending up with rac-7 in quite low yields of 21%.21 After 
quantitative deprotection of the cbz-group under standard conditions, rac-8 was reacted in a peptide 
coupling with 9 using HOAt and HATU as coupling reagents and DIPEA as base to obtain the 
fluorescent labeled TAA derivative rac-10 in 20% yield (Scheme 3). If the N-arylation was performed 
with the more reactive non-protected linker in twofold access the desired product rac-8 was 
obtained in slightly higher yield (28%) although a small amount of dimerisation product (3-4%) 
leads to a loss of rac-4, the workup and purification was facilitated. 
 
Scheme 3. Copper-catalyzed N-arylation of rac-4, if necessary deprotection and subsequent amide bond 
formation with dye 9 leading to fluorescent compound rac-10. Reaction conditions: (a) CuI, L-proline, K2CO3, dry 
DMSO, 100 °C, 48 h. (b) Pd/C, H2, THF, RT, 24 h. (c) HATU, HOAt, DIPEA, DMF, 0 °C to RT, 24 h.  
 
2.2.2  Fluorescent TAA building block in peptide synthesis 
Next, the pyrene labeled TAA rac-3 was incorporated into a short peptide to check if the sterical 
demanding residue affects the peptide coupling (Scheme 4). Compound rac-3 was quantitative 
deprotected at the N-terminus with HCl saturated diethyl ether cleaving the Boc protecting group 
selectively and resulting in the hydrochloride salt of rac-3. This was immediately coupled with N-
acetyl-L-proline 11 in the presence of HOAt and HATU as coupling reagent and DIPEA as base to 
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afford the two diastereomeric dipeptides 12a and 12b in good yield (70% for 12a), which were 
separated by flash column chromatography on silica gel. 
 
Scheme 4. Incorporation of rac-3 into a short peptide. Reaction conditions: (a) HCl sat. Et2O, DCM, RT, 3 h. (b) 
Compound 11, HATU, HOAt, DIPEA, DCM, RT, 48 h. 
 
2.2.3  Post-functionalization of small peptides with fluorescent label 
The synthetic strategy used for the preparation of rac-6 is also suitable for the labeling of various 
small peptides after they have been assembled. Compound 15a which already adopts a β-turn I 
conformation as known from the earlier investigations19 can easily be synthesized by standard 
peptide coupling reaction of rac-13 with the hydrochloride salt of L-alanine benzyl amide in 60% 
yield. Whereas rac-13 is obtained from rac-4 through complete deprotection and once more Boc-
protection like already described. The mixture of 15a/b is again reacted in a Suzuki coupling with 5 
under identical conditions to receive 16a/b in moderate yields of 54% (Scheme 5). The separation of 
these diastereomeric peptides can be done be standard column chromatography on silica gel. 
 
Scheme 5. Functionalization of small TAA containing peptides 15a/b with 1-pyrenyl boronic acid. Reaction 
conditions: (a) EDC, HOBt, DIPEA, DCM, RT, 24 h. (b) Pd(PPh3)4, K2CO3, DME/H2O (1:1), 80 °C, 24 h.  
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The synthesis of tetrapeptide 23 shown in Scheme 6 starts with N-Boc protected racemic 
tetrahydrofuran amino acid rac-13, which was coupled with the hydrochloride salt of S-alanine 
methyl ester employing EDC, HOBt and DIPEA as coupling reagents to give the diastereomeric 
dipeptides 18a (60%) and 18b. After separation by column chromatography compound 18a was 
deprotected at the C-terminus with 1 molar aqueous LiOH solution providing the free acid 19 
quantitatively. Under these mild conditions no racemization on the α-carbon of alanine occurs. 
Compound 19 was then coupled using the same activation reagents with the hydrochloride salt of 
glycine methyl ester providing tripeptide 21 in high yield of 87%. Finally the N-terminal quantitative 
deprotection was realized with HCl saturated diethyl ether, followed by peptide coupling reaction 
with 22 using HOAt and HATU for activation resulting in 23% of compound 23. As an additional 
example a fluorescent pyrene moiety was attached to compound 18a by metal-catalyzed coupling 
reaction under phase transfer conditions using Pd(OAc)2 as catalyst in the presence of Na2CO3 as base 
and TBAB as phase transfer catalyst. The product 18c was obtained in a moderate to good yield of 
57% which is in a comparable range like the other synthetic protocol used before.  
 
Scheme 6. Synthesis of helical structured tetrapeptide 23 and exemplary labeling of the intermediate dipeptide 
18a with a pyrene moiety. Reaction conditions: (a) 17, EDC, HOBt, DIPEA, DMF, RT, 24 h. (b) LiOH (1M), 
MeCN/H2O (4:1), RT, 24 h. (c) 20, EDC, HOBt, DIPEA, DMF, RT, 24 h. (d) HCl sat. Et2O, DCM, RT, 3 h. (e) 
Compound 22, HATU, HOAt, DIPEA, DMF, RT, 24 h. (f) 1-pyrenyl boronic acid 5, Pd(OAc)2, TBAB, Na2CO3, 
DMF/H2O (1:1), 100 °C, 20 h. 
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2.2.4  UV/Vis- and fluorescene measurements 
The absorption and emission spectra for all synthesized compounds carrying a pyrenyl moiety (rac-
3, rac-6, 12a, 16a, 16b and 18c) were recorded in a concentration range of 5x10-6 to 5x10-5 mol/L in 
MeOH solution and can be found in the supporting information (section 2.4.3, Figure 3). For the 
fluorescence measurements all compounds were excited at a wavelength of 343 nm. The spectra of 
rac-3 and rac-6 at 3.0x10-5 mol/L in MeOH are exemplary compared in Figure 2. The absorption 
spectra of rac-3 shows maxima at λ (ε) = 343 nm (45900), 276 nm (46000) and 243 nm (66400). The 
absorption maxima for rac-6 are located at λ (ε) = 343 nm (29900), 278 nm (39500) and 243 nm 
(42600) and are therefore quite identical indicating no red shift for rac-6. In both spectra intense 
bands with high molar extinction coefficients (log ε ≥ 4 2) at the lowest energy peak (243 nm) are 
present which are typically expected for π-π* transitions 54 The fine structure of rac-3 is more 
pronounced whereas in the case of rac-6 the absorption bands are broadened.  
 
 
Figure 2. Comparison of the absorption (at top) and emission (below) spectra of compounds rac-3 (red) and 
rac-6 (blue) at a concentration of 3x10-5 mol/L dissolved in MeOH. 
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This behavior can be explained by the loss of vibrational structure of the pyrene caused by the 
conjugation of the additional phenyl ring, which is described for 1-phenylpyrene.55-57 
 
The fluorescence spectra revealed emission maxima at 396 nm for rac-3 and at 400 nm for rac-6. 
The observed slightly red-shift of the maximum as well as the loss of vibrational fine structure and 
stronger tailing of compound rac-6 relative to rac-3 can be explained by interaction of the phenyl 
group and the pyrene. In addition the fluorescence quantum yields for both compounds were 
determined using pyrene in cyclohexane (ФF = 0 58) as reference: ФF = 0.24±0.03 (rac-3) and ФF = 
0.09±0.02 (rac-6). The quantum yield of rac-6 is considerably lower than for rac-3 since the 
conjugation of the phenyl group and the pyrene π electrons causes an increase in the non-radiative 
deactivation pathways. 
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2.3 Conclusion 
In conclusion, we have prepared unnatural Cα-tetrasubstituted α-amino acids, which stabilize 
secondary peptide structures and bear a fluorescent pyrene or carboxyfluorescein moiety. The 
compounds are useful as peptidomimetics. To illustrate their synthetic feasibility the building blocks 
were incorporated in a short peptide. Furthermore we showed for different short peptides that the 
introduction of a fluorescent dye after the peptide synthesis is possible using the same metal-
catalyzed reactions on the bromoarene substituent. The absorption and emission spectra of the 
prepared building blocks and peptides were investigated. For two building blocks the fluorescence 
quantum yields were determined and found significantly smaller than the parent chromophore 
pyrene. 
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2.4  Experimental Section 
2.4.1  General methods and materials 
Melting point. Melting points were determined on a Stanford Research System OptiMelt melting 
point apparatus 100 and are uncorrected. 
IR spectra. IR spectra were recorded with a Bio-Rad FT-IR-FTS 155 spectrometer and a Bio-Rad 
Excalibur series FT-IR-spectrometer FTS 2000 MX using a Specac Golden Gate Mk II ATR accessory 
where stated. 
NMR spectra. NMR spectra were recorded with Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz, T 
= 300 K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), and Bruker Avance 600 (1H: 
600.1 MHz, 13 : 150 1  Hz, T = 300  ) instruments  The chemical shifts are reported in δ [ppm] 
relative to internal standards (solvent residual peak) or external standard (TMS). The spectra were 
analyzed by first order, the coupling constants J are given in Hertz [Hz]. Abbreviations of the signals: s 
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet, psq = pseudo quintet, 
dd = double doublet, dt = double triplet, ddd = double double doublet. Integration is determined as 
the relative number of atoms. Assignment of signals in 13C-spectra was determined with DEPT-
technique (pulse angle: 135°) and given as (+) for CH3 or CH, (-) for CH2 and (Cquat.) for quaternary C-
Atoms. Error of reported values: chemical shift: 0.01 ppm for 1H-NMR, 0.1 ppm for 13C-NMR and 0.1 
Hz for coupling constants. The solvent used is reported for each spectrum. 
Mass spectra. MS spectra were recorded on a Varian CH-5 (EI), a Finnigan MAT 95 (CI), a 
ThermoQuest Finnigan TSQ 7000 LC/MS spectrometer and a Finnigan MAT TSQ 7000 (ESI) 
spectrometer for low resolution (LR-MS) and on a Finnigan MAT 95 (FAB) for high resolution (HR-
MS). Xenon served as the ionization gas for FAB. 
Absorption spectroscopy. Absorption spectra were recorded on a Varian Cary Bio 50 UV/VIS/NIR 
Spectrometer using a 1 cm quartz cell from Hellma and UV-grade solvents from Merck (Uvasol®). 
The temperature for all measurements was kept constant at 25 °C. 
Fluorescence spectroscopy. Fluorescence spectra were recorded on a Varian Cary Eclipse 
fluorescence spectrophotometer using 1 cm quartz cells from Hellma and UV-grade solvents from 
Merck (Uvasol®) at a constant temperature of 25 °C.  
Determination of fluorescence quantum yields. As reference agent pyrene (ФF = 0 58, λexc. = 335 
nm)58 dissolved in cyclohexane at a concentration of 3.0*10-5 mol/L was used. The emission spectra 
for compounds rac-3 and rac-6 were recorded at three different combinations of emission and 
excitation slit widths (5 nm/5 nm, 5 nm/10 nm, 10 nm/5 nm), while PMT voltage was hold constant 
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at 600V (for both compounds) and 550V in the case of pyrene. The samples were dissolved in 
methanol at a concentration of 3.0*10-5 mol/L and excited with 343 nm. Then integrals ∫  of 
solvent-baseline corrected spectra were calculated and absorption spectra for all compounds were 
measured. According to the equation below, the fluorescence quantum yields ФF for each compound 
at all slit width combinations were calculated and finally given as mean ± s.d. of these three slit width 
combinations. 
 
       
 
       
    
       
     
 
∫      
∫     
 (
 
     
 
    
)
 
  
      
 
 
TLC analysis and column chromatography. TLC analyses were performed on silica gel coated 
alumina plates (Merck 60 F254 Silica gel, layer thickness 0.2 mm). Visualization was done by UV-light 
at 254 nm / 366 nm and/or through staining with ninhydrine in EtOH. For preparative column 
chromatography, Merck Geduran SI 60 (70-230 mesh) and Macherey-Nagel GmbH & Co. KG 60M 
(0.04-0.063 mm, 230-400 mesh) silica gels were used. For chromatography commercially available 
solvents of standard quality were used without further purification. 
Solvents and reagents. Commercial solvents, reagents and starting materials were of analytical 
grade and purchased from Aldrich, Fluka, Merck or Arcos and used without further purification. All 
reactions were performed under an inert atmosphere of N2 using standard Schlenk techniques if not 
otherwise stated. Unless stated otherwise, purification and drying of solvents used was done 
according to accepted general procedures.59,60 
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2.4.2  Syntheses 
The sulfonium salt rac-1, the unnatural amino acid Boc-TAA-OtBu rac-4, respectively Boc-TAA-OH 
rac-13, compound rac-7 as well as the diastereomeric peptides Boc-TAA-(S)-Ala-NHBn 15a/15b and 
Boc-TAA-(S)-Ala-OMe 18a/18b were synthesized according to literature known procedures.19,21 
 
tert-Butyl-3-((tert-butoxycarbonyl)amino)-2-(pyren-1-yl)tetrahydrofuran-3-carboxylate (rac-3): 
An oven or flame dried flask was cooled under a stream of nitrogen and charged with sulfonium 
iodide rac-1 (447 mg, 1.0 mmol, 1.0 eq.) in 4 mL of dry acetonitrile. The colorless solution was cooled 
to 0 °C and powdered KOH (56 mg, 1.0 mmol, 1.0 eq.) was added and the reaction mixture was stirred 
for 15 min. Then pyrene-1-carbaldehyde (207 mg, 0.9 mmol, 0.9 eq.) was added and the mixture was 
stirred for another 2-4 h. After consumption of all the starting material, the reaction mixture was 
quenched by adding water (3 mL). The reaction mixture was diluted with diethyl ether (4 mL) and 
transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted 
with diethyl ether (2 x 5 mL). Then the combined ether layers were washed with brine (5 mL), dried 
over MgSO4 and the solvent was removed in vacuo. The crude product was then purified by flash 
column chromatography on silica gel eluting with petroleum ether/diethyl ether 17:3. The pure 
product was obtained as yellow solid in 56% yield (245 mg, 0.51 mmol). 
Rf (PE/Et2O = 17:3) = 0.18. – Mp: 159-161 °C. – 1H-NMR (400 
MHz, CDCl3): δ = 0 80 (s, 9H, 10), 1 58 (s, 9H, 1), 2 80-2.99 (m, 2H, 11), 
4.44 (dd, 3JH,H = 8.7 Hz, 3JH,H = 16.2 Hz, 1H, 12), 4.55 (ddd, 2JH,H = 3.8 Hz, 
3JH,H = 8.2 Hz, 3JH,H = 8.2 Hz, 1H, 12), 5.73 (bs, 1H, 5), 6.23 (bs, 1H, 14), 
7.97-8.31 (m, 9H, Ar-CH). – 13C-NMR (100 MHz, CDCl3): δ = 27.2 (+, 
3C, CH3), 28.5 (+, 3C, CH3), 36.2 (-, 1C, CH2), 68.3 (-, 1C, OCH2), 71.0 
(Cquat., 1C, CCH3), 80.2 (Cquat., 1C, CNH), 82.4 (Cquat., 1C, CCH3), 82.5 (+, 
1C, OCH), 123.0 (+, 1C, Ar-CH), 124.5 (Cquat., 1C, Ar-C), 124.7 (+, 1C, Ar-
CH), 124.8 (Cquat., 1C, Ar-C), 125.0 (+, 1C, Ar-CH), 125.2 (+, 1C, Ar-CH), 125.3 (+, 1C, Ar-CH), 125.9 (+, 
1C, Ar-CH), 127.4 (+, 1C, Ar-CH), 127.5 (+, 1C, Ar-CH), 127.5 (+, 1C, Ar-CH), 128.7 (Cquat., 1C, Ar-C), 
130.6 (Cquat., 1C, Ar-C), 131.0 (Cquat., 1C, Ar-C), 131.2 (Cquat., 1C, Ar-C), 131.4 (Cquat., 1C, Ar-C), 154.6 
(Cquat., 1C, CONH), 169.7 (Cquat., 1 C, CO). – MS [ESI, CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 
488.3 (90) [MH]+, 505.0 (100) [MNH4]+, 992.7 (100) [2MNH4]+. – Anal. calcd. (%) for C30H33NO5 
(487.59): C 73.90, H 6.82, N 2.87, found: C 73.80, H 7.17, N 2.58. – IR (KBr) [cm-1]: ν = 3359, 2974, 
2867, 2830, 1750, 1703, 1506, 1454. – UV ( eOH): λ (ε) = 343 (45900), 276 (46000), 243 (66400). – 
MF: C30H33NO5. – MW: 487.59. 
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tert-Butyl-3-((tert-butoxycarbonyl)amino)-2-(4-(pyren-1-yl)phenyl)tetrahydrofuran-3-
carboxylate (rac-6): 
In a three-neck round bottom flask potassium carbonate (137 mg, 0.99 mmol, 3.3 eq.) was dissolved 
in 2.5 mL of water. The mixture was purged with nitrogen for 10 min. Under nitrogen with stirring 
compound rac-4 (132 mg, 0.30 mmol), 1-pyrenyl boronic acid 5 (66 mg, 0.27 mmol, 0.9 eq.) and 2.5 
mL of 1,2-dimethoxyethane were added. After 2 min the catalyst Pd(PPh3)4 (26 mg, 3.5% molar 
amount) was added and the mixture was stirred for 5 min. The resulting mixture was then heated to 
reflux in an oil bath at 70 °C for 24 hours. After cooling down to room temperature, water (5 mL) was 
added and the mixture was extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried 
over MgSO4 and the solvent was removed under reduced pressure. The crude product was purified 
by flash column chromatography on silica gel eluting with petroleum ether/ethyl acetate 3:1. The 
pure product was obtained as yellow solid in 63% yield (96 mg, 0.17 mmol). 
 Rf (PE/EtOAc = 3:1) = 0.24. – Mp: 173.1-174.5 °C. – 1H-
NMR (600 MHz, COSY, CDCl3): δ = 1 26 (s, 9H, 10), 1 55 (s, 9H, 
1), 2.65-2.80 (m, 1H, 11a/b), 2.81-2.92 (m, 1H, 11a/b), 4.27-4.38 
(m, 1H, 12a/b), 4.44 (ddd, 2JH,H = 3.8 Hz, 3JH,H = 8.2 Hz, 3JH,H = 8.2 
Hz, 1H, 12a/b), 5.22 (bs, 1H, 14), 5.77 (bs, 1H, 5), 7.57 (d, 3JH,H = 
8.1 Hz, 2H, 16), 7.61 (d, 3JH,H = 8.2 Hz, 2H, 17), 7.92 (d, 3JH,H = 
7.8 Hz, 1H, Ar-CH), 7.97-8.03 (m, 2H, Ar-CH), 8.06-8.10 (m, 2H, 
Ar-CH), 8.13-8.17 (m, 2H, Ar-CH), 8.17-8.21 (m, 2H, Ar-CH). – 
13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ = 27 5 (+, 3 , 10), 
28.4 (+, 3C, 1), 36.0 (-, 1C, 11), 68.0 (-, 1C, 12), 69.9 (Cquat., 1C, 6), 80.0 (Cquat., 1C, 2), 82.3 (Cquat., 1C, 9), 
85.5 (+, 1C, 14), 124.6 (+, 1C, Ar-CH), 124.8 (+, 1C, Ar-CH), 124.8 (Cquat., 1C, Ar-C), 124.9 (Cquat., 1C, Ar-
C), 125.0 (+, 1C, Ar-CH), 125.1 (+, 1C, Ar-CH), 126.0 (+, 1C, Ar-CH), 126.4 (+, 2C, 16), 127.3 (+, 1C, Ar-
CH), 127.4 (+, 1C, Ar-CH), 127.4 (+, 1C, Ar-CH), 128.4 (Cquat., 1C, Ar-C), 130.1 (+, 2C, 17), 130.5 (Cquat., 
1C, Ar-C), 130.9 (Cquat., 1C, Ar-C), 131.4 (Cquat., 1C, Ar-C), 136.7 (Cquat., 1C, 15), 137.3 (Cquat., 1C, Ar-C), 
140.8 (Cquat., 1C, 18), 154.5 (Cquat., 1C, 4), 170.1 (Cquat., 1C, 7). – MS (ESI, CH2Cl2/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 564.2 (100) [MH]+, 581.3 (50) [MNH4]+, 605.3 (35) [MH+MeCN]+, 1127.9 (50) 
[2MH]+, 1144.9 (100) [2MNH4]+, 1149.8 (65) [2MNa]+. – HR-MS (PI-LSIMS, MeOH/CH2Cl2/NBA): 
[MH]+ calcd. for C36H37NO5 564.2750, found 564.27543. – Anal. calcd. (%) for C36H37NO5 (563.68): C 
76.71, H 6.62, N 2.48, found: C 76.36, H 6.78, N 2.40. – IR (neat) [cm-1]: ν = 2977, 2883, 1699, 1604, 
1488, 1364, 1253, 1157, 1067, 842, 720, 682. – UV ( eOH): λ (ε) = 343 (29900), 278 (39500), 243 
(42600). – MF: C36H37NO5. – MW: 563.68. 
  
 2 Pyrene labeled Cα-tetrasubstituted α-amino acids as building blocks for fluorescent peptidomimetics 
 
26 
tert-Butyl 2-(4-((2-aminoethyl)amino)phenyl)-3-((tert-butoxycarbonyl)-amino)tetrahydrofuran-3-
carboxylate (rac-8): 
To a solution of compound rac-7 (66 mg, 0.12 mmol) in 2 mL of THF, Pd/C (2.5 mg, 20% molar 
amount) as catalyst was added. Afterwards the mixture was stirred over night at room temperature 
under an atmosphere of H2 (20 bar). The catalyst was filtered off, washed with THF and the solvent 
was removed under reduced pressure. The crude product was purified by flash column 
chromatography on silica gel eluting with ethyl acetate/ethanol 1:1. The pure product was obtained 
as yellow solid in 97% yield (48 mg, 0.11 mmol). 
Rf (EtOAc/EtOH = 1:1) = 0.42. – 1H-NMR (300 MHz, 
CDCl3): δ = 1 15 (s, 9H, 10), 1 45 (s, 9H, 1), 2.43-2.57 (m, 
1H, 11a/b), 2.69-2.83 (m, 1H, 11a/b), 3.23 (t, 3JH,H = 5.8 Hz, 
2H, 21), 3.46 (dd, 3JH,H = 5.9 Hz, 3JH,H = 11.7 Hz, 2H, 20), 
4.08 (dd, 3JH,H = 7.4 Hz, 3JH,H = 14.4 Hz, 1H, 12a/b), 4.27 
(ddd, 2JH,H = 3.7 Hz, 3JH,H = 8.3 Hz, 3JH,H = 8.3 Hz, 1H, 12a/b), 
4.78 (bs, 1H, 14), 5.44 (bs, 1H, 5), 6.32 (bs, 1H, 19), 6.51 (d, 3JH,H = 8.5 Hz, 2H, 16/17), 7.08 (d, 3JH,H = 
8.5 Hz, 2H, 16/17). – MS [ESI, CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 421.3 (100) [MH]+, 
462.3 (25) [MH+MeCN]+. – IR (neat) [cm-1]: ν = 3368, 2975, 2930, 1695, 1614, 1510, 1487, 1366, 
1298, 1256, 1157, 1070, 1030, 934, 797, 734. – MF: C22H35N3O5. – MW: 421.53. 
 
4-((2-((4-((2R,3S)-3-(tert-Butoxycarbonyl)-3-((tert-butoxycarbonyl)amino)-tetrahydrofuran-2-
yl)phenyl)amino)ethyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (rac-10): 
Under an atmosphere of nitrogen compound 9 (34 mg, 0.09 mmol) was dissolved in 0.6 mL of dry 
DMF and cooled to 0 °C in an ice bath. To this solution DIPEA (38 µL, 0.22 mmol, 2.5 eq.), HOAt (15 
mg, 0.105 mmol, 1.2 eq.) and HATU (40 mg, 0.105 mmol, 1.2 eq.) were added. Afterwards compound 
rac-8 (45 mg, 0.105 mmol, 1.2 eq.) was slowly added in several portions. After the addition was 
completed, the mixture was allowed to reach room temperature and stirred for 24 hours. The 
reaction was quenched with 2 mL of water and acidified with 0.5 mL of 1M KHSO4 solution and 
extracted with diethyl ether (3 x 5 mL). The combined organic layers were washed with brine (5 mL), 
dried over MgSO4 and the solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography on silica gel eluting with petroleum ether/ethyl acetate 1:2. 
The pure product was obtained as yellow solid in 20% yield (14 mg, 0.018 mmol). 
 Rf (PE/EtOAc = 1:2) = 0.19. – 1H-NMR (300 MHz, CDCl3): δ = 1 20 (s, 9H, 10), 1 48 (s, 9H, 1), 2 44-
2.56 (m, 1H, 11a/b), 2.67-2.80 (m, 1H, 11a/b), 3.23-3.35 (m, 2H, 21), 3.45-3.61 (m, 2H, 20), 4.06 (dd, 
3JH,H = 7.2 Hz, 3JH,H = 14.0 Hz, 1H, 12a/b), 4.26 (ddd, 2JH,H = 3.6 Hz, 3JH,H = 8.1 Hz, 3JH,H = 8.1 Hz, 1H, 12a/b), 
4.81 (bs, 1H, 14), 5.46 (bs, 1H, 5), 5.91 (s, 1H, Ar-CH), 6.04 (bs, 1H, 22), 6.31 (bs, 1H, 19), 6.40-6.48 
(m, 2H, Ar-CH), 6.50 (d, 3JH,H = 8.4 Hz, 2H, 16/17), 6.80-6.95 (m, 2H, Ar-CH), 7.06 (d, 3JH,H = 8.4 Hz, 2H,  
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 16/17), 7.19 (d, 3JH,H = 8.3 Hz, 1H, Ar-CH), 
8.01 (d, 3JH,H = 8.2 Hz, 1H, Ar-CH), 8.20-8.31 
(m, 2H, Ar-CH). – MS [ESI, CH2Cl2/MeOH + 
10 mmol/l NH4OAc): m/z (%) = 780.8 (100) 
[MH]+, 821.8 (45) [MH+MeCN]+. – IR (neat) 
[cm-1]: ν = 3545, 3360, 2978, 2933, 1691, 
1602, 1517, 1482, 1360, 1291, 1251, 1152, 
1063, 1026, 931, 798, 743. – MF: C43H45N3O11. – MW: 779.83. 
 
(2R,3S)-tert-Butyl 3-((S)-1-acetylpyrrolidine-2-carboxamido)-2-(pyren-1-yl)tetrahydrofuran-3-
carboxylate (12a): 
Compound rac-3 (100mg, 0.21 mmol) was dissolved in 3 mL of CH2Cl2. To this solution 2 mL HCl 
saturated diethyl ether solution (9.5 mL/mmol Boc) was added and stirred for 20 min at room 
temperature. The solvent was evaporated by vacuo and the resulting light yellow solid was dissolved 
in 3 mL of dry CH2Cl2 followed by N-acetylated L-proline (39 mg, 0.25 mmol), HOAt (16.7 mg, 0.12 
mmol), HBTU (95 mg, 0.25 mmol) and DIPEA (133 mg, 1.25 mmol). The reaction was stirred at room 
temperature for 2 days, quenched with 2 mL of 1M KHSO4 solution, diluted with 4 mL of EtOAc and 
transferred to a separatory funnel. The aqueous layer was extracted with EtOAc (2 x 3 mL). The 
combined EtOAc layers were washed with 3 mL of brine solution, dried over MgSO4 and the solvent 
was removed in vacuo. The crude product was purified by flash column chromatography on silica gel 
using 40-45% ethyl acetate in dichloromethane as eluent. The pure product was obtained with a yield 
of 75% (40 mg, 0.076 mmol). 
Rf (EtOAc/DCM = 1:1) = 0.20. – Mp: 159-161 °C. – 1H-NMR (400 MHz, 
COSY, CDCl3): δ = 0 62 (s, 9H, 14), 1 93-2.05 (m, 2H, 6a/b+5a/b), 2.12 (s, 3H, 
1), 2.14-2.24 (m, 1H, 5a/b), 2.37-2.43 (m, 1H, 6a/b), 2.67 (ddd, 2JH,H = 2.6 Hz, 
3JH,H = 6.7 Hz, 3JH,H = 12.9 Hz, 1H, 15a/b), 3.00 (ddd, 2JH,H = 8.4 Hz, 3JH,H = 9.7 
Hz, 3JH,H = 12.9 Hz, 1H, 15a/b), 3.47 (ddd, 2JH,H = 6.8 Hz, 3JH,H = 9.4 Hz, 3JH,H = 
9.5 Hz, 1H, 4a/b), 3.63-3.70 (m, 1H, 4a/b), 4.40 (ddd, 2JH,H = 6.7 Hz, 3JH,H = 8.3 
Hz, 3JH,H = 9.7 Hz, 1H, 16a/b), 4.54 (ddd, 2JH,H = 2.6 Hz, 3JH,H = 8.2 Hz, 3JH,H = 8.2 
Hz, 1H, 16a/b), 6.29 (bs, 1H, 18), 7.95-8.34 (m, 9H, Ar-CH). – 13C-NMR (100 
MHz, HSQC, HMBC, CDCl3): δ = 22 5 (+, 1 , 1), 25.1 (-, 1C, 5), 26.9 (+, 3C, 
14), 28.0 (-, 1C, 6), 36.4 (-, 1C, 15), 48.5 (-, 1C, 4), 60.2 (+, 1C, 7), 68.5 (-, 1C, 
16), 71.5 (Cquat., 1C, 13), 82.1 (Cquat., 1C, 10), 83.1 (+, 1C, 18), 123.5 (+, 1C, Ar-CH), 124.5 (Cquat., 1C, Ar-
C), 124.6 (+, 1C, Ar-CH), 124.7 (Cquat., 1C, Ar-C), 125.0 (+, 1C, Ar-CH), 125.2 (+, 1C, Ar-CH), 125.3 (+, 1C, 
Ar-CH), 125.8 (+, 1C, Ar-CH), 127.4 (+, 1C, Ar-CH), 127.4 (+, 1C, Ar-CH), 127.5 (+, 1C, Ar-CH), 128.7 
(Cquat., 1C, Ar-C), 130.6 (Cquat., 1C, Ar-C), 131.0 (Cquat., 1C, Ar-C), 131.3 (Cquat., 1C, Ar-C), 131.6 (Cquat., 1C, 
Ar-C), 169.0 (Cquat., 1C, CO), 170.9 (Cquat., 1C, CO), 171.0 (Cquat., 1C, CO). – MS [ESI, CH2Cl2/MeOH + 10 
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mmol/l NH4OAc): m/z (%) = 527.2 (100) [MH]+, 544.2 (20) [MNH4]+, 568.3 (10) [MH+MeCN]+, 1053.7 
(60) [2MH]+, 1070.7 (20) [2MNH4]+. – Anal. calcd. (%) for C32H34N2O5 (526.62): C 72.98, H 6.51, N 
5.32, found: C 72.70, H 6.77, N 5.30. – IR (KBr) [cm-1]: ν = 3258, 3223, 3049, 2976, 2889, 1923, 1730, 
1685, 1618, 1550, 1452, 1430. – UV ( eOH): λ (ε) = 343 (30600), 276 (32000), 243 (45400). – MF: 
C32H34N2O5. – MW: 526.62. 
 
tert-Butyl (3-(((S)-1-(benzylamino)-1-oxopropan-2-yl)carbamoyl)-2-(4-(pyren-1-yl)phenyl)tetra-
hydrofuran-3-yl)carbamate(16): 
In a three-neck round bottom flask potassium carbonate (80 mg, 0.58 mmol, 3.3 eq.) was dissolved in 
1.5 mL of water. The mixture was purged with nitrogen for 10 min. Under nitrogen with stirring a 
mixture of dipeptides 15a and 15b (89 mg, 0.17 mmol), 1-pyrenyl boronic acid (38 mg, 0.15 mmol, 
0.9 eq.) and 1.5 mL of 1,2-dimethoxyethane were added. After 2 min the catalyst Pd(PPh3)4 (15 mg, 
3.5% molar amount) was added and the mixture was stirred for 5 min. The resulting mixture was 
then heated to reflux in an oil bath at 70 °C for 24 hours. After cooling down to room temperature, 
water (5 mL) was added and the mixture was extracted with CH2Cl2 (3 x 5 mL). The combined organic 
layers were dried over MgSO4 and the solvent was removed under reduced pressure. The crude 
product was purified by flash column chromatography on silica gel using 20-25% EtOAc in hexanes 
as eluent. The pure products were obtained with an overall yield of 54% (54 mg, 0.081 mmol) as light 
yellow 16a and colorless solid 16b. 
16a: Rf (PE/EtOAc = 3:1) = 0.22. – Mp: 110 °C. – 1H-NMR 
(400 MHz, COSY, CDCl3): δ = 1.06 (d, 3JH,H = 7.0 Hz, 3H, 25), 
1.51 (s, 9H, 1), 2.45-2.62 (m, 1H, 17a/b), 2.74-2.99 (m, 1H, 
17a/b), 4.15-4.25 (m, 1H, 9), 4.35-4.46 (m, 4H, 12+18), 5.57 
(bs, 1H, 20), 6.20 (bs, 1H, 5), 6.27 (bs, 1H, 11), 6.69 (d, 3JH,H = 
7.3 Hz, 1H, 8), 7.14-7.26 (m, 5H, 14-16), 7.51-7.59 (m, 4H, 
22+23), 7.88-8.22 (m, 9H, Ar-CH). – 13C-NMR (100 MHz, 
HSQC, HMBC, CDCl3): δ = 17 6 (+, 1 , 25), 28.4 (+, 3C, 1), 36.1 
(-, 1C, 17), 43.6 (-, 1C, 12), 49.1 (+, 1C, 9), 66.7 (-, 1C, 18), 
67.8 (Cquat., 1C, 6), 80.2 (Cquat., 1C, 2), 81.5 (+, 1C, 20), 124.6 
(+, 1C, Ar-CH), 124.9 (+, 1C, Ar-CH), 124.9 (Cquat., 1C, Ar-C), 
125.0 (Cquat., 1C, Ar-C), 125.2 (+, 1C, Ar-CH), 125.3 (+, 1C, Ar-CH), 126.0 (+, 1C, Ar-CH), 127.4 (+, 2C, 
Ar-CH), 127.4 (+, 1C, Ar-CH), 127.5 (+, 1C, Ar-CH), 127.5 (+, 1C, Ar-CH), 127.5 (+, 2C, Ar-CH), 127.6 (+, 
2C, Ar-CH), 128.4 (Cquat., 1C, Ar-C), 128.7 (+, 1C, Ar-CH), 128.7 (+, 1C, Ar-CH), 130.3 (+, 2C, Ar-CH), 
130.6 (Cquat., 1C, Ar-C), 130.9 (Cquat., 1C, Ar-C), 131.5 (Cquat., 1C, Ar-C), 136.1 (Cquat., 1C, Ar-C), 137.1 
(Cquat., 1C, Ar-C), 137.7 (Cquat., 1C, Ar-C), 140.5 (Cquat., 1C, Ar-C), 154.3 (Cquat., 1C, 4), 171.4 (Cquat., 1C, 7), 
171.4 (Cquat., 1C, 10). – MS [ESI, CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 668.3 (100) [MH]+, 
690.4 (20) [MNa]+, 1336.0 (60) [2MH]+. – HR-MS (PI-LSIMS, MeOH/CH2Cl2/NBA): [MH]+ calcd. for 
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C42H41N3O5 667.3046, found 667.3039. – IR (neat) [cm-1]: ν = 3309, 3043, 2977, 2927, 1693, 1645, 
1497, 1366, 1158, 1074, 843, 722. – UV ( eOH): λ (ε) = 343 (23600), 278 (30200), 243 (34000). – 
MF: C42H41N3O5. – MW: 667.79. 
 
16b: Rf (PE/EtOAc = 3:1) = 0.26. – Mp: 124 °C. – 1H-NMR 
(400 MHz, COSY, CDCl3): δ = 1.18 (d, 3JH,H = 7.2 Hz, 3H, 25), 
1.43 (s, 9H, 1), 2.45-2.60 (m, 1H, 17a/b), 2.94-3.08 (m, 1H, 
17a/b), 4.09-4.20 (m, 1H, 9), 4.21-4.37 (m, 3H, 12+18a/b), 4.47 
(ddd, 2JH,H = 4.3 Hz, 3JH,H = 8.6 Hz, 3JH,H = 8.7 Hz, 1H, 18a/b), 
5.17 (bs, 1H, 20), 5.78 (bs, 1H, 5), 6.34 (d, 3JH,H = 6.3 Hz, 1H, 
8), 6.56 (bs, 1H, 11), 7.03-7.21 (m, 5H, 14-16), 7.50 (d, 3JH,H = 
8.2 Hz, 2H, 22), 7.55 (d, 3JH,H = 8.2 Hz, 2H, 23), 7.83-8.24 (m, 
9H, Ar-CH). – 13C-NMR (100 MHz, HSQC, HMBC, CDCl3): δ = 
18.1 (+, 1C, 25), 28.3 (+, 3C, 1), 36.5 (-, 1C, 17), 43.4 (-, 1C, 
12), 49.4 (+, 1C, 9), 67.6 (-, 1C, 18), 69.2 (Cquat., 1C, 6), 81.3 
(Cquat., 1C, 2), 85.1 (+, 1C, 20), 124.7 (+, 1C, Ar-CH), 124.9 (+, 1C, Ar-CH), 124.9 (Cquat., 1C, Ar-C), 125.0 
(Cquat., 1C, Ar-C), 125.3 (+, 1C, Ar-CH), 126.1 (+, 1C, Ar-CH), 126.1 (+, 1C, Ar-CH), 127.2 (+, 2C, Ar-CH), 
127.4 (+, 1C, Ar-CH), 127.5 (+, 1C, Ar-CH), 127.6 (+, 1C, Ar-CH), 127.7 (+, 2C, Ar-CH), 127.7 (+, 2C, Ar-
CH), 128.4 (Cquat., 1C, Ar-C), 128.5 (+, 1C, Ar-CH), 128.6 (+, 1C, Ar-CH), 130.5 (+, 2C, Ar-CH), 130.7 
(Cquat., 1C, Ar-C), 130.9 (Cquat., 1C, Ar-C), 131.5 (Cquat., 1C, Ar-C), 135.7 (Cquat., 1C, Ar-C), 136.9 (Cquat., 1C, 
Ar-C), 138.1 (Cquat., 1C, Ar-C), 141.2 (Cquat., 1C, Ar-C), 155.3 (Cquat., 1C, 4), 170.5 (Cquat., 1C, CO), 171.7 
(Cquat., 1C, CO). – MS [ESI, CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 668.3 (100) [MH]+, 685.3 
(40) [MNH4]+, 690.3 (20) [MNa]+, 1336.0 (60) [2MH]+. – HR-MS (PI-LSIMS, MeOH/CH2Cl2/NBA): 
[MH]+ calcd. for C42H41N3O5 667.3046, found 667.3048. – IR (neat) [cm-1]: ν= 3428, 3042, 2976, 2930, 
1649, 1603, 1554, 1366, 1155, 1072, 844, 723. – UV ( eOH): λ (ε) = 343 (27800), 278 (37200), 243 
(41200). – MF: C42H41N3O5. – MW: 667.79. 
 
(S)-Methyl 2-((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-(4-(pyren-1-yl)phenyl)tetrahydrofuran-3-
carboxamido)propanoate (18c): 
In a 10 mL Schlenk flask were placed compound 18a (50 mg, 0.11 mmol), 1-pyrenyl boronic acid 5 
(31 mg, 0.13 mmol, 1.2 eq.), Na2CO3 (45 mg, 0.42 mmol, 3.8 eq.) Pd(OAc)2 (2 mg, 6 µmol), tetrabutyl 
ammonium bromide (34 mg, 0.11 mmol, 1.0 eq.) and 1 mL a water / DMF (1:1) mixture. The flask was 
sealed with a septum and placed into an oil bath preheated to 100°C. The reaction mixture was 
stirred at this temperature for 20 h. Then the mixture was allowed to cool to room temperature, 
water and diethyl ether (5 mL of each) were added. The phases were separated and the aqueous 
phase was extracted three times with 5 mL of diethyl ether. The combined organic phases were dried 
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over MgSO4, filtered and the solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography on silica gel eluting with petroleum ether/ethyl acetate 3:1. 
The pure product was obtained as yellow solid in 57% yield (37 mg, 0.06 mmol). 
Rf (PE/EtOAc = 3:1) = 0.28. – Mp: 168.3-179.7 °C. – 1H-
NMR (400 MHz, CDCl3): δ = 0.89 (d, 3JH,H = 7.0 Hz, 3H, 21), 1.52 
(s, 9H, 1), 2.64-2.81 (m, 1H, 13a/b), 2.83-2.92 (m, 1H, 13a/b), 
3.67 (s, 3H, 12), 4.03-4.10 (m, 1H, 9), 4.25-4.37 (m, 1H, 14a/b), 
4.40-4.47 (m, 1H, 14a/b), 5.20 (bs, 1H, 16), 5.75 (bs, 1H, 5), 6.03 
(d, 3JH,H = 8.2 Hz, 1H, 8), 7.58 (d, 3JH,H = 8.0 Hz, 2H, 18), 7.64 (d, 
3JH,H = 8.1 Hz, 2H, 19), 7.90-7.93 (m, 1H, Ar-CH), 7.97-8.04 (m, 
2H, Ar-CH), 8.06-8.11 (m, 2H, Ar-CH), 8.13-8.17 (m, 2H, Ar-CH), 
8.17-8.21 (m, 2H, Ar-CH). – 13C-NMR (100 MHz, CDCl3): δ = 
17.8 (+, 1C, 21), 28.3 (+, 3C, 1), 36.4 (-, 1C, 13), 48.9 (+, 1C, 9), 
52.5 (+, 1C, 12), 68.1 (-, 1C, 14), 69.9 (Cquat., 1C, 6), 80.2 (Cquat., 1C, 2), 86.3 (+, 1C, 16), 124.6 (+, 1C, Ar-
CH), 124.8 (+, 1C, Ar-CH), 124.8 (Cquat., 1C, Ar-C), 124.9 (Cquat., 1C, Ar-C), 125.0 (+, 1C, Ar-CH), 125.1 (+, 
1C, Ar-CH), 126.0 (+, 1C, Ar-CH), 126.6 (+, 2C, 18), 127.2 (+, 1C, Ar-CH), 127.4 (+, 1C, Ar-CH), 127.4 (+, 
1C, Ar-CH), 128.4 (Cquat., 1C, Ar-C), 130.2 (+, 2C, 19), 130.5 (Cquat., 1C, Ar-C), 130.9 (Cquat., 1C, Ar-C), 
131.4 (Cquat., 1C, Ar-C), 136.7 (Cquat., 1C, 15), 137.3 (Cquat., 1C, Ar-C), 141.2 (Cquat., 1C, 20), 154.7 (Cquat., 
1C, 4), 170.2 (Cquat., 1C, 7), 172.9 (Cquat., 1C, 10). – MS [ESI, CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z 
(%) = 593.7 (100) [MH]+, 610.7 (30) [MNH4]+, 634.7 (40) [MH+MeCN]+, 1186.4 (20) [2MH]+. – IR 
(neat) [cm-1]: ν = 3325, 2977, 2888, 1696, 1599, 1488, 1354, 1251, 1150, 1061, 842, 722, 687. – UV 
( eOH): λ (ε) = 343 (30500), 278 (43200), 243 (47400). – MF: C36H36N2O6. – MW: 592.68. 
 
(S)-2-((2R,3S)-2-(4-Bromophenyl)-3-(tert-butoxycarbonylamino)tetrahydro-furan-3-carbox-
amido)propanoic acid (19): 
Compound 18a (150mg, 0.32 mmol) was dissolved in 8 mL of an acetonitrile/water mixture (4:1). 
Under stirring a 1M aqueous LiOH solution (0.35 mL, 0.35 mmol, 1.1 eq.) was added drop by drop. 
The mixture was stirred over night at room temperature. After acidification with 1M aqueous KHSO4 
solution, the mixture was extracted with dichloromethane (3 x 10 mL). The combined organic layers 
were dried over MgSO4 and concentrated under reduced pressure to give the product as colorless 
solid in analytical pure form and quantitative yield (145 mg, 0.32 mmol). 
Mp: 59.6-60.9 °C. – 1H-NMR (300 MHz, MeOH-d4): δ= 0.80 (d, 3JH,H = 7.1 Hz, 3H, 20), 1.45 (s, 9H, 1), 
2.14-2.28 (m, 1H, 12a/b), 2.97-3.12 (m, 1H, 12a/b), 3.98 (dd, 3JH,H = 8.5 Hz, 3JH,H = 16.2 Hz, 2H, 13), 4.31 
(dt, 3JH,H = 3.3 Hz, 3JH,H = 8.4 Hz, 1H, 9), 4.88 (s, 1H, 15), 7.27 (d, 3JH,H = 8.4 Hz, 2H, 17), 7.44 (d, 3JH,H = 
8.5 Hz, 2H, 18). – 13C-NMR (75 MHz, MeOH-d4): δ = 18 1 (+, 1 , 20), 28 7 (+, 3 , 1), 36 7 (-, 1C, 12), 
49.4 (+, 1C, 9), 68.6 (-, 1C, 13), 71.6 (Cquat., 1C, 6), 81.4 (Cquat., 1C, 2), 87.3 (+, 1C, 15), 123.1 (Cquat., 1C,  
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19), 130.1 (+, 2C, 17), 132.1 (+, 2C, 18), 138.5 (Cquat., 1C, 16), 157.1 
(Cquat., 1C, 4), 163.0 (Cquat., 1C, 7), 175.5 (Cquat., 1C, 10). – MS [ESI, 
CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 456.9 (100) [MH]+, 
497.9 (5) [MH+MeCN]+. – IR (neat) [cm-1]:  = 2984, 2936, 1704, 1663, 
1509, 1487, 1451, 1392, 1366, 1250, 1160, 1070, 1011, 847, 794, 
587. – MF: C19H25BrN2O6. – MW: 457.32. 
 
Methyl 2-((S)-2-((2R,3S)-2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydro-furan-3-
carboxamido)propanamido)acetate (21): 
Under an atmosphere of nitrogen compound 19 (145 mg, 0.32 mmol) was dissolved in 2 mL of dry 
DMF and cooled to 0 °C in an ice bath. To this solution DIPEA (135 µL, 0.79 mmol, 2.5 eq.), HOBt (60 
mg, 0.44 mmol, 1.4 eq.) and EDC (67 µL, 0.38 mmol, 1.2 eq.) were added. Afterwards the 
hydrochloride salt of glycine methylester 20 (48 mg, 0.38 mmol, 1.2 eq.) was slowly added in several 
portions. After the addition was completed, the mixture was allowed to reach room temperature and 
stirred for 24 hours. The reaction was quenched with 2 mL of water and acidified with 1.5 mL of 1M 
KHSO4 solution and extracted with diethyl ether (3 x 5 mL). The combined organic layers were 
washed with brine, dried over MgSO4 and the solvent was removed under reduced pressure. The 
crude product was purified by flash column chromatography on silica gel eluting with petroleum 
ether/ethyl acetate 4:6.. The pure product was obtained as colorless solid in 84% yield (140 mg, 0.26 
mmol). 
Rf (PE/EtOAc = 4:6) = 0.22. – Mp: 162.6-164.5 °C. – 1H-NMR 
(600 MHz, COSY, ROESY, CDCl3): δ = 1.08 (d, 3JH,H = 5.5 Hz, 3H, 
24), 1.44 (s, 9H, 1), 2.47-2.57 (m, 1H, 16a/b), 2.76-2.85 (m, 1H, 
16a/b), 3.69 (s, 3H, 15), 3.73-3.80 (m, 1H, 12), 3.84-3.90 (m, 1H, 
12), 4.04-4.11 (m, 1H, 9), 4.15-4.22 (m, 1H, 17a/b), 4.34 (dt, 3JH,H 
= 3.9 Hz, 3JH,H =8.7 Hz, 1H, 17a/b), 5.09 (bs, 1H, 19), 6.07 (bs, 1H, 
5), 6.36 (d, 3JH,H = 4.7 Hz, 1H, 8), 6.51-6.56 (m, 1H, 11), 7.19 (d, 
3JH,H = 8.4 Hz, 2H, 21), 7.40 (d, 3JH,H = 8.4 Hz, 2H, 22). – 13C-NMR 
(150 MHz, HSQC, HMBC, CDCl3): δ = 17 4 (+, 1 , 24), 28 3 (+, 3 , 
1), 36.1 (-, 1C, 16), 41.0 (-, 1C, 12), 48.8 (+, 1C, 9), 52.2 (+, 1C, 15), 67.1 (-, 1C, 17), 68.7 (Cquat., 1C, 6), 
81.0 (Cquat., 1C, 2), 83.2 (+, 1C, 19), 121.9 (Cquat., 1C, 23), 127.5 (+, 2C, 21), 131.3 (+, 2C, 22), 135.9 
(Cquat., 1C, 20), 155.1 (Cquat., 1C, 4), 169.8 (Cquat., 1C, 13), 170.5 (Cquat., 1C, 7), 171.9 (Cquat., 1C, 10). – MS 
[ESI, CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 471.9 (15) [MH–C4H8]+, 527.9 (90) [MH]+, 545.0 
(100) [MNH4]+. – Anal. calcd. (%) for C22H30BrN3O7 (528.39): C 50.01, H 5.72, N 7.95, found: C 49.13, 
H 5.87, N 7.81. – IR (neat) [cm-1]: ν= 3328, 2976, 1748, 1669, 1648, 1544, 1498, 1452, 1366, 1252, 
1207, 1158, 1069, 1003, 872, 797, 647. – MF: C22H30BrN3O7. – MW: 528.39. 
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Methyl 2-((S)-2-((2R,3S)-3-amino-2-(4-bromophenyl)tetrahydrofuran-3-carboxamido)propan-
amido)acetate hydrochloride(21b): 
Compound 21 (100 mg, 0.19 mmol) was dissolved under ice bath cooling at 0 °C in CH2Cl2. Under 
vigorous stirring 1.3 mL of ice-cold HCl saturated diethyl ether (7 mL/mmol Boc) was added and the 
mixture was stirred for 3 hours. The solvent was removed under reduced pressure to give the HCl 
salt of the product as a white to yellow solid in quantitative yield (88 mg, 0.19 mmol). 
Mp: > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 1.26 (d, 3JH,H 
= 7.0 Hz, 3H, 20), 2.38-2.49 (m, 1H, 12a/b), 2.82-2.94 (m, 1H, 12a/b), 
3.75 (s, 3H, 11), 3.86-4.02 (m, 2H, 8), 4.06-4.25 (m, 2H, 5+13a/b), 
4.51 (dt, 3JH,H = 2.9 Hz , 3JH,H = 9.0 Hz, 1H, 13a/b), 4.98 (s, 1H, 15), 
7.26 (d, 3JH,H = 8.4 Hz, 2H, 17), 7.49 (d, 3JH,H = 8.5 Hz, 2H, 18). – 13C-
NMR (75 MHz, MeOH-d4): δ = 19.2 (+, 1C, 20), 36.0 (-, 1C, 12), 41.9 
(-, 1C, 8), 50.4 (+, 1,C, 5), 52.6 (+, 1C, 11), 67.6 (-, 1C, 13), 69.4 
(Cquat., 1C, 2), 86.2 (+, 1C, 15), 123.9 (Cquat., 1C, 19), 129.4 (+, 2C, 17), 
132.7 (+, 2C, 18), 135.1 (Cquat., 1C, 16), 168.2 (Cquat., 1C, 9), 171.4 
(Cquat., 1C, 3), 173.9 (Cquat., 1C, 6). – MS [ESI, CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 427.9 
(100) [MH]+, 468.9 (12) [MH+MeCN]+. – IR (neat) [cm-1]: ν = 3310, 2943, 1741, 1659, 1517, 1443, 
1214, 1076, 1009, 814, 595. – MF: C17H22BrN3O5 x HCl. – MW: 464.74. 
 
(S)-tert-Butyl 4-acetamido-5-(((2R,3S)-2-(4-bromophenyl)-3-(((S)-1-((2-methoxy-2-oxoethyl) 
amino)-1-oxopropan-2-yl)carbamoyl)tetrahydrofuran-3-yl)amino)-5-oxopentanoate (23): 
Under an atmosphere of nitrogen N-acetylated L-glutamic acid 22 (55 mg, 0.22 mmol) was dissolved 
in 1.3 mL of dry DMF and cooled to 0 °C in an ice bath. To this solution DIPEA (96 µL, 0.56 mmol, 2.5 
eq.), HOAt (37 mg, 0.27 mmol, 1.2 eq.) and HATU (102 mg, 0.27 mmol, 1.2 eq.) were added. 
Afterwards compound 21b (88 mg, 0.19 mmol, 0.9 eq.) was slowly added in several portions. After 
the addition was completed, the mixture was allowed to reach room temperature and stirred for 24 
hours. The reaction was quenched with 2 mL of water and acidified with 1.5 mL of 1M KHSO4 solution 
and extracted with diethyl ether (3 x 5 mL). The combined organic layers were washed with brine 
(10 mL), dried over MgSO4 and the solvent was removed under reduced pressure. A first purification 
of the crude product was done by flash column chromatography on silica gel eluting with petroleum 
ether/ethyl acetate 2:8. The final purification was achieved by preparative HPLC using a Knauer 
HPLC system with a Phenomenex Luna 10 C18(2) 250x21.x mm 10 micron column. The detection 
wavelength was at 220 nm, column temperature 25 °C, injection volume 200 µL, solvent A: H2O 
[0.0059 % TFA w/w], solvent B: MeCN. Gradient 0 min 30% B, 30 min 60% B, 40 min 95% B, 50 min 
95% B; flow rate 11 mL/min. Eluation time: 15.1 min. The pure product was obtained as white solid 
in a yield of 3% (3.5 mg, 5 µmol). 
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Rf (PE/EtOAc= 2:8) = 0.27. – 1H-NMR (600 MHz, COSY, 
ROESY, DMSO-d6): δ = 0.80 (d, 3JH,H = 7.2 Hz, 3H, 31), 1.39 (s, 9H, 
22), 1.71-1.79 (m, 1H, 17a/b), 1.88 (s, 3H, 1), 1.89-1.96 (m, 1H, 
17a/b), 2.00-2.06 (m, 1H, 23a/b), 2.21-2.31 (m, 2H, 18), 2.79-2.88 
(m, 1H, 23a/b), 3.58 (s, 3H, 16), 3.70-3.78 (m, 3H, 10+13.), 3.83-
3.88 (m, 1H, 24a/b), 4.17-4.25 (m, 2H, 4+24a/b), 5.06 (s, 1H, 26), 
7.22 (d, 3JH,H = 8.5 Hz, 2H, 28), 7.29 (d 3JH,H = 7.2 Hz, 1H, 9), 7.46 
(d 3JH,H = 8.5 Hz, 2H, 29), 7.73 (t, 3JH,H = 6.0 Hz, 1H, 12), 8,15 (d, 
3JH,H = 6.6 Hz, 1H, 3), 8.79 (s 1H, 6). – 13C-NMR (150 MHz, HSQC, 
HMBC, DMSO-d6): δ = 16.9 (+, 1C, 31), 22.4 (+, 1C, 1), 26.2 (-, 1C, 
17), 27.7 (+, 3C, 22), 31.4 (-, 1C, 18), 34.7 (-, 1C, 23), 40.4 (-, 1C, 13), 48.0 (+, 1C, 10), 51.6 (+, 1C, 16), 
52.8 (+, 1C, 4), 67.1 (-, 1C, 24), 69.8 (Cquat., 1C, 7), 79.7 (Cquat., 1C, 21), 84.3 (+, 1C, 26), 120.9 (Cquat., 1C, 
30), 128.7 (+, 2C, 28), 130.4 (+, 2C, 29), 137.7 (Cquat., 1C, 27), 168.0 (Cquat., 1C, 8), 169.7 (Cquat., 1C, 14), 
170.1 (Cquat., 1C, 2), 171.6 (Cquat., 1C, 19), 172.2 (Cquat., 1C, 11),173.0 (Cquat., 1C, 5). – MS [ESI, 
CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 599.3 (10) [MH–C4H8]+, 657.3 (20) [MH]+, 679.3 
(100) [MNa]+. – HR-MS (PI-LSIMS, MeOH/CH2Cl2/NBA): [MH]+ calcd. for C28H39BrN4O9 655.1979, 
found 655.19925. – IR (neat) [cm-1]: ν= 3295, 2979, 1727, 1650, 1534, 1447, 1368, 1202, 1155, 1075, 
1011, 838, 799, 650, 600. – MF: C28H39BrN4O9. – MW: 655.53. 
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2.4.3  Supporting Information 
1H-NMR spectra of compound rac-3 (400 MHz, CDCl3): 
13C-NMR spectra of compound rac-3 (100 MHz, CDCl3):
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1H-NMR spectra of compound rac-6 (600 MHz, CDCl3):  
 
13C-NMR spectra of compound rac-6 (150 MHz, CDCl3): 
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1H-NMR spectra of compound 12a (400 MHz, CDCl3):  
 
13C-NMR spectra of compound 12a (100 MHz, CDCl3): 
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1H-NMR spectra of compound 16a (400 MHz, CDCl3):  
 
13C-NMR spectra of compound 16a (100 MHz, CDCl3): 
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1H-NMR spectra of compound 16b (400 MHz, CDCl3):  
 
13C-NMR spectra of compound 16b (100 MHz, CDCl3): 
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1H-NMR spectra of compound 21 (600 MHz, CDCl3):  
 
13C-NMR spectra of compound 21 (150 MHz, CDCl3): 
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1H-NMR spectra of compound 23 (600 MHz, DMSO-d6):  
 
13C-NMR spectra of compound 23 (150 MHz, DMSO-d6): 
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UV/Vis- and fluorescence spectra: 
a) 
 
b) 
 
c) 
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UV/Vis- and fluorescence spectra: 
d) 
 
e) 
 
f) 
Figure 3. Absorption (left) and emission (right) spectra of pyrene labeled compounds in the concentration range 
of 5x10-6 to 5x10-5 mol/L dissolved in MeOH. Excitation wavelength for emission was 343 nm. (a) Compound 
rac-3 (b) Compound rac-6 (c) Compound 12a (d) Compound 16a (e) Compound 16b (f) Compound 18c.  
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Crystal structure analysis of compound rac-3: 
 
 
 
 
Crystal Data 
Empirical formula   C30H33NO5 
Formula weight    487.57 
Crystal size    0.410 x 0.060 x 0.020 mm 
Crystal description   flat needle 
Crystal colour    colourless 
Crystal system    Monoclinic 
Space group    P 21/c 
Unit cell dimensions   a = 5.88530(10) Å   α = 90º 
b = 20.9715(3) Å   β = 91 4300(10)º 
c = 20.6745(3) Å   γ = 90º 
Volume    2550.93(7) Å3 
Z, Calculated density   4, 1.270 Mg/m3 
Absorption coefficient  0.692 mm-1 
F(000)    1040 
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Crystal structure analysis of compound 18a: 
 
 
 
 
Crystal Data 
Empirical formula   C20H27BrN2O6 
Formula weight    471.34 
Crystal size    0.340 x 0.085 x 0.024 mm 
Crystal description   thin plate 
Crystal colour    colourless 
Crystal system    Monoclinic 
Space group    P 21 
Unit cell dimensions   a = 10.7567(4) Å   α = 90º 
b = 6.1367(3) Å    β = 102 512(3)º 
c = 16.4151(6) Å   γ = 90º 
Volume    1057.84(8) Å3 
Z, Calculated density   2, 1.477 Mg/m3 
Absorption coefficient   1.981 mm-1 
F(000)    486 
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Crystal structure analysis of compound 18b: 
 
 
 
 
Crystal Data 
Empirical formula   C20H27BrN2O6 
Formula weight    471.34 
Crystal size    0.270 x 0.140 x 0.140 mm 
Crystal description   needle 
Crystal colour    colourless 
Crystal system    Monoclinic 
Space group    P 21 
Unit cell dimensions  a = 10.7776(14) Å   α = 90º 
b = 6.1129(13) Å   β = 91 201(13)º 
c = 16.069(3) Å    γ = 90º 
Volume    1058.4(3) Å3 
Z, Calculated density   2, 1.456 Mg/m3 
Absorption coefficient   2.937 mm-1 
F (000)     488 
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3 Synthesis of new NTS2 selective NT(8-13) peptide analogues by the 
incorporation of a Cα-tetrasubstituted amino acid by SPPS 
 
This chapter describes the synthesis of a small peptide library incorporating HCl*H-TAA-OH 1 by 
solid phase supported peptide synthesis into the lead structure NT(8-13). In one series 1 is used as 
scaffold for Tyr11-Ile12 and in a second series it replaces only Tyr11 leading to new NT(8-13) peptide 
mimetics. Biological investigations employing a radioligand binding assay were performed, revealing 
selectivity towards hNTS2. 
 
 
 
 
 
 
 
 
 
 
All compounds which are described in this chapter were synthesized by Michael Dobmeier. The 
radioligand binding studies and the data analysis of the primary data were performed by Dr. Harald 
Hübner, Department of Chemistry and Pharmacy Emil Fischer Center, Friedrich Alexander University, 
Erlangen.1   
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3.1 Introduction 
The tridecapeptide pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH is known as the 
neuropeptide neurotensin,2,3 which is located and produced in the gastrointestinal tract, the central 
nervous system and the brain.4 Acting as a neuromodulator, a wide range of biological functions is 
mediated by the binding of neurotensin to three different neurotensin receptors which are known so 
far. The neurotensin receptor 1 (NTS1)5,6 and also the neurotensin receptor 2 (NTS2)7,8 belong to the 
class A of G-protein coupled receptors (GPCRs),9 which are responsible for most of the biological 
effects related with neurotensin. Receptor subtype 3 (NTS3)10 is part of the Vps10p family of sorting 
receptors11 and consists only of one single transmembrane domain. Besides neurotensin NTS3 can 
bind various other ligands, e.g. lipoprotein lipase or apo lipoprotein A, but binding of neurotensin is 
inhibiting the binding of all other ligands. NTS3 is probably involved in the neurotensin signaling.12 
The different physiological effects, which are associated with NTS1 are analgesic and antipsychotic 
properties as well as the control of dopamine-mediated neuroleptic effects leading to the opinion that 
NTS1 play a major role in psychiatric and neurological diseases,13 e.g. in the pathogenesis of 
Parkinson’s Disease14 or schizophrenia.15 Moreover NTS1 stimulation is regarded to be involved in 
the promotion of cancer growth.16-20 NTS2 is related with hypothermia,21 antipsychotic properties22 
and the promotion of µ-opioid-independent antinociception23-25 as an important part in the 
modulation of tonic pain sensitivity.26,27 In the past early investigations proofed that the C-terminal 
fragment NT(8-13) is representing the pharmacological active part28,29 of Neurotensin and became 
therefore the most applied lead structure for the development of NTS1 respectively NTS2 selective 
ligands as therapeutic agents or for the use in imaging. Recently the group of Grisshammer was able 
to co-crystalize a mutant of NTS1 in the active bound state with NT(8-13)30 providing valuable 
information about the binding mode and the bioactive conformation as basis for a rational design of 
new neurotensin peptide analogues. This was the first report of a crystal structure of NTS1 or NTS2. 
Therefore structure-activity-relationship studies of the last two decades were less rationally guided. 
In the beginning investigations mainly focused towards the NTS1, but with revealing negative aspects 
like promotion of cancer cell growth the studies today are mainly focussing on NTS2 selective ligands. 
These ligands are seen as highly interesting candidate for drug development since they show activity 
in the modulation of tonic pain sensitivity. The huge range of structural modification of the lead 
structure NT(8-13) include D-amino acid scans,31,32 alanine scans,33 homo-β-amino acid scans,34 
backbone modifications introducing conformational constraints,35 side chain modifications,36 N-
terminal modifications,37,38 C-terminal modifications,39 peptide-peptoid hybrids40 (N-homotyrosine), 
incorporation of proline derivatives,41 modifications for metabolically stability42 (Nα-methylarginine). 
Further modifications are containing 18F substituents43,44 for PET imaging or radioisotopes for 
tumors treatment.45-47 
We recently reported the synthesis of the Cα-tetrasubstituted tetrahydrofuran amino acid (TAA) 1 
and investigated their stereochemical properties. Incorporated in small peptides, the dipeptide 
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mimetic 1 induces two consecutive β turns leading to the formation of stable secondary structures48 
and stable peptide helices.49 The bromo substituent was used for synthetic modifications to prepare 
cyclic peptides,50 attach fluorescent labels (see Chapter 2) or further modifications of the side chain.51 
 
Figure 1. Incorporation of compound 1 as modification of NT(8-13) leading to the target structures 2 and 3. 
Herein we report a structure-activity-relationship study, based on a small peptide library of new NTS 
ligands analogous to the lead structure NT(8-13) depicted in Figure 1. In this approach either Tyr11-
Ile12 is replaced by the TAA building block 1 (blue) leading to peptides of type 2 or only the tryrosine 
residue is exchanged (red) resulting in compounds of type 3. The new compounds are expected to 
show NTS2 selective properties in biological testing.  
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3.2  Results and Discussion 
3.2.1  Syntheses 
TAA building block. The unnatural amino acid building block HCl*H-TAA-OH 1 was prepared 
according to a literature known procedure, which was developed in our laboratory.48 The five-step 
synthesis started from commercial available methionine with N-Boc protection, esterification with 
tert-butanol and methylation of the side-chain by treatment with methyl iodide. The key step was an 
aldol-type reaction of the ester enolate formed under strong basic conditions with 4-
bromobenzaldehyde followed by an intramolecular nucleophilic substitution to build up the 
tetrahydrofurane core. The deprotonation of the α-carbon is accompanied by a loss of stereochemical 
information. Together with the non-stereospecific substitution reaction this resulted in the formation 
of in total four stereoisomers (trans/cis-ratio: 97:3). Final deprotection with 6.0 M hydrochloric acid 
gave compound 1 in a good overall yield of 54%. The building block was used as racemic mixture of 
the two trans-isomers (αS,βR) respectively (αR,βS) in the peptide synthesis.  
Peptide synthesis. The target peptides 2 and 3 were synthesized by solid phase supported peptide 
synthesis (SPPS) applying a standard protocol for Fmoc-strategy.52,53 Commercial available Wang 
resin and Fmoc protected α-amino acids: Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-
OH and Fmoc-Arg(Pbf)-OH were used. 
 
Scheme 2. Synthesis of target compounds 2a and 2b. Reaction conditions: (a) Fmoc-AA-OH, TBTU, HOBt, DIPEA, 
DMF, RT, 3.5 h (2x). (b) Ac2O, DIPEA, DMF, RT, 1 h. (c) piperidine/DMF (40:60, v/v), RT, 5 min followed by 
piperidine/DMF (20:80,v/v), RT, 10 min. (d) TBTU, HOBt, DIPEA, DMF, RT, 3.5 h (2x). (e) TFA/TIS/water 
(90:5:5, v/v), RT, 3 h respectively 30 min.  
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The coupling reaction was enabled by the presence of TBTU, HOBt and DIPEA as activation reagents 
and performed twice to increase the yield of the coupling products. After every amino acid (except for 
1) an acylation reaction using Ac2O and DIPEA in DMF was carried out to cap unreacted amino 
groups and prevent complex product mixtures, which complicate the purification. Cleavage of the 
Fmoc group required treatment with pyridine in DMF twice. Protection of 1 was not necessary as 
known from earlier investigations: Due to the high steric demand of the Cα-tetrasubstituted amino 
acids, homo coupling of building block 1 is entirely excluded.49,54,55 Final cleavage from the resin was 
performed with a mixture TFA/TIS/water, employing TIS as cation scavenger to prevent alkylation of 
nucleophilic functional groups in the peptides during side-chain deprotection.56-58 As a consequence 
of the racemic compound 1 the peptides of type 2 were obtained as couples of two diasteromers. The 
purification and separation was achieved by preparative HPLC giving eight pentapeptides 2a-h with 
moderate yields. Peptides 2a and 2b are exemplary presented in Scheme 1 and for 2c-h see Figure 2. 
 
Figure 2. Structures and yields of the synthesized pentapeptides 2c-h. 
The preparation of type 3 peptides only replacing the Tyr moiety by 1 was done as described above. 
Purification by preparative chromatography did not allow to separate the two diastereomers 
completely. With the diasteromeric peptide mixtures 3ad-gh (Figure 3) in our hands we decided to 
continue with the pharmacological investigations and postponed the separation and identification of 
the stereochemically pure peptides  The preliminary stereochemical assignment of (αS,βR) or (αR,βS) 
for type 2 and type 3 peptides is based on the chromatography retention time in comparison with 
previous investigations.48,49,54 For a final proof of the assignment the stereocontrolled synthesis of at 
least one pair of peptides as described below or a crystal structure of one target molecules is 
necessary. Two dimensional NMR investigations and variable temperature 1H-NMR in an appropriate 
solvent like DMSO-d6 leads to very complex spectra and does not allow an assignment. In summary 
the use of compound 1 as racemic mixtures allows a very fast, flexible and convenient synthesis of a 
small peptide library in a non-stereocontrolled fashion. These stereoisomeric mixtures were used for 
an initial pharmacological investigation.  
Besides target peptides 2 and 3 two more hexapeptides 4a and 4b (Figure 3) were synthesized via 
SPPS using commercial available Fmoc-(S)-Phe(4-Br)-OH or Fmoc-(R)-Phe(4-Br)-OH. Those 
compounds serve as reference compounds and should indicate the effect of the Br-substituent and 
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the conformational rigidification of the peptide back-bone on the biological activity. Moreover they 
show, which stereochemistry in α-position of the TAA is preferred for high activity.  
 
Figure 3. Structures and yields of synthesized hexapeptides 3ab-gh and compounds 4a and 4b.  
Stereoselective synthesis. To have a direct synthetic access to single stereoisomers, which show 
interesting activity in the initial testing, we investigated the crucial steps of an alternative reaction 
route using a similar strategy, which we applied several times in solution peptide synthesis, 
illustrated in Scheme 2.  
 
Scheme 3. Stereoselective preparation of TAA containing and Fmoc protected building blocks 6a/6b 
respectively 7a/7b for SPPS. Reaction conditions: (a) Fmoc-Cl, Na2CO3, dioxane/water, RT, 2 h. (b) HCl*H-Ile-
OtBu, EDC*HCl, HOBt, DIPEA, DCM, RT, 24 h. (c) TFA, DCM, RT, 1 h.59 
Compound 1 was first Fmoc protected yielding compound 5 after optimization in a yield of 51%, 
which is considered good taking into account the significant steric hindrance of the starting material. 
Then 5 was coupled in the present of HOBt, EDC*HCl and DIPEA with the hydrochloride salt of 
isoleucine tert-butyl ester yielding the diastereomeric compounds 6a and 6b. The separation of both 
fully protected dipeptides was achieved by standard flash column chromatography on silica gel. The 
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separability depends on the protecting groups, the natural amino acid and the direction of the 
synthesis. Coupling the N-terminus of 1 with a natural amino acid leads to inseparable mixtures of 
dipeptides. Bulky protecting groups hamper the separation in general. In solution phase chemistry 
(e.g. see Chapter 2) Boc groups and Me-esters were used. To have the peptides compatible with 
Fmoc-strategy on SPPS Fmoc/TBDMS-ester and Fmoc/tert-butyl ester were tried. However, in the 
first case the separation was not successful, while with tert-butyl the separation gave only low yields. 
The stereochemistry of 6a/6b was proven by 2-dimensional NMR experiments (NOESY) and variable 
temperature 1H-NMR to determine the temperature coefficients of the NH-protons, which indicates 
the present or absence of hydrogen bonds. The chemical shifts of the NH-protons fit to literature 
know values.54 The deprotection of the carboxylic ester groups leads to SPPS compatible building 
blocks 7a/7b as single stereoisomers for the synthesis of type 3 peptides. The synthesis of single 
stereoisomers of hexapeptides 3a or 3b was not possible during the timeframe of this work.  
 
3.2.2  Biological investigations 
For the determination of binding affinities of compounds 2a-h, 3ab-gh and 4a/4b towards NTS1 and 
NTS2 receptors a radioligand displacement assay was performed (Table 1). In the case of NTS1 the 
radioligand [3H]neurotensin and stably transfected Chinese hamster ovary (CHO) cells expressing 
human NTS1 were used. Binding data for NTS2 receptor were collected employing human embryonic 
kidney (HEK293) cells which were transiently transfected with the pcDNA3.1 vector containing the 
hNTS2 gene against [3H]NT(8-13) as radioactive reference agent.  
The pentapeptides 2a-h show Ki values in the range of 53-100 µM for NTS1 and 1-49 µM for NTS2 
and hence can be regarded as inactive. This may be rationalized by the crystal structure of the 
activating NT(8-13) bound to NTS1, which was recently published by Grisshammer and co-workers.30 
The absence of Ile12 leads to an insufficient distance between the C-terminal carboxylic group and the 
bulky sterically demanding TAA. As a consequence the formation of hydrogen bonds between Leu13 
of type 2 compounds and Y146 and R327 of the receptor is not possible or restricted leading to lower 
binding affinities. However interestingly all compounds showed binding selectivity towards NTS2, 
which is in accordance with the structural data available that indicate NTS2 is tolerating changes at 
position of Tyr11 more easily than NTS1.60-62 Moreover a clear preference for one possible 
stereochemistry is present  according to our assignment (αS,βR) is superior to (αR,βS)  
The binding data for the hexpeptides 3ab-gh revealed Ki(NTS2) values in the nanomolar region (67-
227 nM) and all compounds show a about 50fold selectivity over NTS1. From the results of 
compound 4a/4b in comparison with 2g/2h and 3gh we concluded that the bromo substituent has 
no significant influence on the binding affinity or selectivity. The selectivity of 2h (αR,βS) is identical 
to 4b (R) and the Ki values of 3gh and 4a/4b are in a similar range taking in account that 3gh is the 
average value of the active and the less active isomer. Comparison of 2g with 4a suggested that for 
the selectivity the rigidification and the right stereochemistry of the peptide back bone are crucial. 
Peptides 4a/4b can adopt several conformations and also 2h can still undergo some conformational  
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Table 1. Binding data of target compounds 2a-h, 3ab-3dh and 4a,b at the human NTS1 and NTS2 receptor 
determined via radioligand binding assay relative to the reference agent NT(8-13).63 
Compd Sequence Ki [nM][a] SR[f] 
  hNTS1[b] hNTS2[c]  
NT(8-13) H-Arg-Arg-Pro-Tyr-Ile-Leu-OH 0.24±0.024 1.2 ± 0.17[d] 0.20 
     
2a H-Arg-Arg-Pro-(αS,βR)-TAA-Leu-OH 72500 ± 38900[e] 1430 ± 440 51 
2b H-Arg-Arg-Pro-(αR,βS)-TAA-Leu-OH 91500 ± 4900 49300 ± 15300 1.9 
2c H-Arg-Lys-Pro-(αS,βR)-TAA-Leu-OH >100000 ± 0[e] 5800 ± 2000 17 
2d H-Arg-Lys-Pro-(αR,βS)-TAA-Leu-OH 70500 ± 41700[e] 16000 ± 5600[e] 4.4 
2e H-Lys-Arg-Pro-(αS,βR)-TAA-Leu-OH 92300 ± 7700 11100 ± 870 8.3 
2f H-Lys-Arg-Pro-(αR,βS)-TAA-Leu-OH 53000 ± 2800[e] 28000 ± 21200[e] 1.9 
2g H-Lys-Lys-Pro-(αS,βR)-TAA-Leu-OH 95500 ± 6300[e] 2030 ± 290 47 
2h H-Lys-Lys-Pro-(αR,βS)-TAA-Leu-OH 67000 ± 46700[e] 26500 ± 7800[e] 2.5 
     
3ab 
H-Arg-Arg-Pro-(αS,βR)-TAA-Ile-Leu-OH 
H-Arg-Arg-Pro-(αR,βS)-TAA-Ile-Leu-OH 
3500 ± 830 67 ± 12 52 
3cd 
H-Arg-Lys-Pro-(αS,βR)-TAA-Ile-Leu-OH 
H-Arg-Lys-Pro-(αR,βS)-TAA-Ile-Leu-OH 
9900 ± 2970 147 ± 23 68 
3ef 
H-Lys-Arg-Pro-(αS,βR)-TAA-Ile-Leu-OH 
H-Lys-Arg-Pro-(αR,βS)-TAA-Ile-Leu-OH 
5000 ± 750 110 ± 0[e] 46 
3gh 
H-Lys-Lys-Pro-(αS,βR)-TAA-Ile-Leu-OH 
H-Lys-Lys-Pro-(αR,βS)-TAA-Ile-Leu-OH 
12600 ± 2470 227 ± 66 56 
     
4a H-Lys-Lys-Pro-(S)-Phe(4-Br)-Ile-Leu-OH 93 ± 22 69 ± 9 1.3 
4b H-Lys-Lys-Pro-(R)-Phe(4-Br)-Ile-Leu-OH 2170 ± 540 873 ± 265 2.5 
[a] Values are the means ± SEM of 3-6 individual experiments, each done in triplicate. [b] 
Determined with [3H]neurotensin and membranes from CHO cells stably expressing human NTS1. 
[c] Determined with [3H]NT(8-13) and homogenates from HEK293 cells transiently expressing 
human NTS2. [d] KD value. [e] Values are the means ± SD of two individual experiments, both done 
in triplicate. [f] Selectivity ratio: Ki(NTS1)/Ki(NTS2). 
changes since the (αR,βS)-TAA building block is not inducing a rigid secondary structure element. 
Whereas (αS,βR)-TAA leads to two consecutive type I β-turns and consequently exerts a larger 
impact on the conformation of the peptide 2g resulting in an increased selectivity.  
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3.3  Conclusion and Outlook 
In conclusion we have reported the synthesis of a new class of NTS2 receptor selective ligands based 
on the structural modification of the lead structure NT(8-13) via SPPS. Compound 1 was introduced 
as scaffold for Tyr or Tyr-Ile, respectively, leading to a small library of penta- and hexapeptides. For 
selected peptides that showed interesting biological activity when tested as mixtures of 
stereoisomers the crucial steps of an alternative synthetic pathway were investigated. This 
stereoselective synthesis will lead to diastereomerically pure compounds.  
The biological investigations by radioligand binding assay at hNTS1 or hNTS2 receptors revealed that 
target compounds 2a-h have only very low affinity and were therefore not further investigated. The 
Ki values for compounds 3ab-dh showed good binding affinities and increased selectivity towards 
the NTS2 receptor. The most promising compound 3ab has a Ki(NTS2) value of 67 ± 12 nM and a 
selectivity ratio of 52. The most active and selective compound for NTS2 receptor binding reported so 
far has still a significant lower  Ki(NTS2)  = 2.8 ± 0.69 nM and a higher selectivity ratio of: 22000. 
Ongoing investigations regarding the stereochemistry of the biological active isomer of compound 
3ab and concerning the sterical demand of the TAA building block at the binding site of the protein 
are in progress. The active isomer of 3ab should have an estimated Ki(NTS2) of 33-45 nM and also a 
slightly higher selectivity towards NTS2. It would be favorable to resynthesize the compound using 
the indirect route with compounds 7a/7b as it would at the same time clarify the assignment of the 
stereochemistry. Besides a molecular modeling study, the compounds 8a-d are designed to examine 
the sterical demand of these new class of ligands. Finally compounds 9a-d are very interesting 
candidates for potent and selective NTS2 receptor ligands representing a conformational rigidified 
tyrosine mimetic. Compared to the compounds of type 2 and 3 they allow the formation of an 
additional hydrogen bond at the binding site, which should significantly improve the Ki values. 
 
Figure 4. Structures of most favorable compounds 8a-d and 9a-d for ongoing investigations.   
3 Synthesis of new NTS2 selective NT(8-13) peptide analogues by the incorporation of a Cα-
tetrasubstituted amino acid by SPPS 
 
58 
3.4  Experimental Section 
3.4.1  General 
Melting point. Melting points were determined on a Stanford Research System OptiMelt melting 
point apparatus 100 and are uncorrected.  
IR spectra. IR spectra were recorded with a Bio-Rad FT-IR-FTS 155 spectrometer and a Bio-Rad 
Excalibur series FT-IR-spectrometer FTS 2000 MX using a Specac Golden Gate Mk II ATR accessory 
where stated. 
NMR spectra. NMR spectra were recorded with Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz, T 
= 300 K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), and Bruker Avance 600 (1H: 
600.1 MHz, 13 : 150 1  Hz, T = 300  ) instruments  The chemical shifts are reported in δ [ppm] 
relative to internal standards (solvent residual peak) or external standard (TMS). The spectra were 
analyzed by first order, the coupling constants are given in Hertz [Hz]. Abbreviations of the signals: s 
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet, dd = double doublet. 
Integration is determined as the relative number of atoms. Assignment of signals in 13C-spectra was 
determined with DEPT-technique (pulse angle: 135°) and given as (+) for CH3 or CH, (-) for CH2 and 
(Cquat.) for quaternary C-Atoms. Error of reported values: chemical shift: 0.01 ppm for 1H-NMR, 0.1 
ppm for 13C-NMR and 0.1 Hz for coupling constants. The solvent used is reported for each spectrum. 
Mass spectra. MS spectra were recorded on a Finnigan MAT 95 (CI), a ThermoQuest Finnigan TSQ 
7000 LC/MS spectrometer and a Finnigan MAT TSQ 7000 (ESI) spectrometer for low resolution (LR-
MS) and on an Agilent Tech 6540 UHD Accurate Mass Q-TOF LC/MS for high resolution (HR-MS). 
Analytical UHPLC. UHPLC/MSD-System (S3): Agilent 1290 Infinity Bin Pump G4220A, Agilent 1290 
Infinity DAD G4212A, Agilent 1290 Infinity Sampler G4226A, Agilent 1290 TCC G1316C, MSD Agilent 
Quadrupol G6130A, MM-ESI-APCI Multimode-Source G1978B; software: OpenLAB CDS ChemStation 
Rev C.01.0435; column: Phenomenex Luna 3 um C18 (2) 100A, 150 mm x 2.00 mm, column 
temperature: 25 °C; UV detection at 220 nm, 230 nm and 254 nm; gradient: from 0 min 5% 
MeCN/H2O (0.059% TFA), 20 min 33% MeCN/H2O (0.059% TFA), 25 min 98% MeCN/H2O (0.059% 
TFA); Flow rate: 0.3 mL/min, injection volume: 2 µL, sample concentration: 1.0 mg/mL.  
Analytical HPLC. LC/MSD-System (S1): Agilent Technologies 1100 Bin Pump G1312A, 1100 DAD 
G1315B, 1100 Degasser G1379A, ALS G1329A, 1200 FC G1330B, 1100 COLCOM G1316A, MSD Agilent 
Quadrupol G6130A, MM-ESI-APCI Multimode-Source G1978B; software: LC/MSD Chemstation Rev. 
B.04.03; column: Phenomenex Luna 3 um C18 (2) 100A, 150 mm x 2.00 mm , column temperature: 25 
°C; UV detection at 220 nm, 230 nm and 254 nm; gradient: linear from 5% MeCN/H2O (0.059% TFA) 
to 95% MeCN/H2O (0.059% TFA) within 30 min; Flow rate: 0.3 mL/min, injection volume: 3 µL, 
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sample concentration: 1.0 mg/mL. LC-System (S2): Agilent 1100/1 Bin Pump G1312A, DAD G1315B, 
Degasser G1379, ALS G1313A, COLCOM G1316A, FLD G1321A; software: ChemStation for LC 3D 
Systems Rev B.03.01. SR1; column: Phenomenex Luna 3 um C18 (2) 100A, 150 mm x 2.00 mm, 
column temperature: 25 °C, FLD-A, ELS; UV detection at 220 nm, 230 nm and 254 nm, fluorescence 
detection: zero-order; gradient: linear from 5% MeCN/H2O (0.059% TFA) to 95% MeCN/H2O 
(0.059% TFA) within 30 min; Flow rate: 0.3 mL/min, injection volume: 6 µL, sample concentration: 
1.0 mg/mL. 
Preparative HPLC. LC-System: Agilent 1100 Series PrepPump G1361A, PrepPump G1361A, AFC 
G1364A, MWD G1365B, ALS G1329A, ALS Therm G1330B, HPLC Column Chiller/Heater C030: Echo 
Therm Torrey Pines Scientific; software: ChemStation for LC 3D Systems Rev B03.02; column: 
Phenomenex Luna 10 um C18 (2) 100A, 250 mm x 21.2 mm, column temperature: 25 °C; UV 
detection at 220nm; solvents: MeCN (B) / H2O (0.059% TFA) (A); Flow rate: 21.0 mL/min. 
TLC analysis and column chromatography. TLC analyses were performed on silica gel coated 
alumina plates (Merck 60 F254 Silica gel, layer thickness 0.2 mm). Visualization was done by UV-light 
at 254 nm / 366 nm and/or through staining with ninhydrine in EtOH. For preparative column 
chromatography, Merck Geduran SI 60 (70-230 mesh) and Macherey-Nagel GmbH & Co. KG 60M 
(0.04-0.063 mm, 230-400 mesh) silica gels were used. For chromatography commercially available 
solvents of standard quality were used without further purification. Furthermore an automated flash 
column chromatography system Biotage Isolera One with 200-800 nm wavelength detector and 
spectra option was used. 
Solvents and reagents. Commercial solvents, reagents and starting materials were of analytical 
grade and purchased from Aldrich, Fluka, Merck or Arcos and used without further purification. Iris 
Biotech GmbH supplied all Fmoc-protected amino acids, coupling reagents and resins. Unless stated 
otherwise, purification and drying of solvents used was done according to accepted general 
procedures.64,65 
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3.4.2  Syntheses 
The unnatural amino acid HCl*H-TAA-OH 1 was prepared in a five-step synthesis according to a 
literature known procedure.48 
General procedure (GP) for the preparation of target peptides via SPPS. 
All peptides 2a-h, 3ab-gf and 4a/4b were prepared manually using BD discardit II syringes, standard 
Fmoc chemistry and Wang resin (2% DVB, loading 1.0-1.1 mmol g-1). Solvents and soluble reagents 
were removed in various washing steps by vacuo. As side-chain protection groups Boc and Pbf66 were 
applied for Lys respectively Arg during peptide synthesis. Wang resin (50 mg, 50-55 µmol) was 
weighed in a syringe equipped with a frit and swollen in DCM (2 mL) for 60 min. Afterwards, the 
corresponding Fmoc protected amino acid (250 µmol, 5 eq.) was dissolved in 2 mL of DMF and the 
coupling reagents HOBt (250 µmol, 5 eq.), TBTU (245 µmol, 4.9 eq.) and DIPEA (500 µmol, 10 eq.) 
were added and stirred for 1 min. Then the reaction mixture was added to the resin and reacted for 
3.5 h. The resin was washed with 2 mL of DMF, MeOH, DCM and DMF (5 times each). The coupling 
step and washings steps were repeated. Acylation with Ac2O (250 µmol, 5 eq.) and DIPEA (500 µmol, 
10 eq.) in 2 mL of DMF was done for 1 h to eliminate unreacted sites and the resin was washed like 
mentioned above. The removal of the Fmoc group was carried out with piperidine in DMF (40:60, 
v/v) for 5 min followed by (20:80, v/v) for 10 min and washed again with 2 mL DMF, MeOH, DCM, 
DMF (5 times each). The peptide coupling cycles consisting of coupling, acylation, deprotection and 
washing steps were repeated according to the desired peptide sequence. After coupling of HCl*H-
TAA-OH the acylation and deprotection step was skipped. The final cleavage of the peptides from the 
resin and simultaneous side-chain deprotection was achieved by treatment of the peptidyl resin with 
1.5 mL of a TFA/TIS/H2O (90:5:5, v/v) mixture for 3 h followed by 1 mL for 30 min. The combined 
TFA solutions were filtered of from the resin, collected in a Falcon tube and reduced in volume to 
about 0.5 mL under vacuum. Then the peptide was precipitated with ice-chilled Et2O and the 
suspension was centrifuged at -4 °C for 10 min. The solution was carefully taken off and the 
precipitate re-suspended in ice-chilled Et2O and centrifuged again. To remove most of the scavengers 
this procedure of re-suspending/centrifuging was repeated five times. Finally the crude peptide was 
dried under vacuum. The purification was done either by preparative RP-HPLC or by automated flash 
column chromatography on RP-silica gel like stated below.  
H-Arg-Arg-Pro-(αS,βR)-TAA-Leu-OH (2a): 
Synthesized according to the GP. Yield: 4.6 mg, 23%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (20, 65), (22, 98), (32, 98), tR = 10.974 min. – HPLC (analytical, S1): tR = 12.344 
min (DAD), Purity: 92%. – LC/MS (ESI, tR = 12.478 min): m/z (%) = 404.7 (60) [M+2H]2+, 808.3 (100) 
[MH]+. – HR-MS: [M+2H]2+ calcd. for C34H54BrN11O7 404.6768, found 404.6770. – MF: C34H54BrN11O7. 
– MW: 808.77. 
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H-Arg-Arg-Pro-(αR,βS)-TAA-Leu-OH (2b): 
Synthesized according to the GP. Yield: 2.6 mg, 13%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (20, 65), (22, 98), (32, 98), tR = 10.590 min. – HPLC (analytical, S1): tR = 12.038 
min (DAD), Purity: 94%. – LC/MS (ESI, tR = 12.185 min): m/z (%) = 404.7 (100) [M+2H]2+, 808.3 
(100) [MH]+. – HR-MS: [M+2H]2+ calcd. for C34H54BrN11O7 404.6768, found 404.6775. – MF: 
C34H54BrN11O7. – MW: 808.77.  
H-Arg-Lys-Pro-(αS,βR)-TAA-Leu-OH (2c): 
Synthesized according to the GP. Yield: 6.4 mg, 33%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (20, 65), (22, 98), (32, 98), tR = 10.938 min. – HPLC (analytical, S1): tR = 12.162 
min (DAD), Purity: 98%. – LC/MS (ESI, tR = 12.297 min): m/z (%) = 390.7 (30) [M+2H]2+, 780.3 (100) 
[MH]+. – HR-MS: [M+2H]2+ calcd. for C34H54BrN9O7 390.6738, found 390.6738. – MF: C34H54BrN9O7. – 
MW: 780.75.  
H-Arg-Lys-Pro-(αR,βS)-TAA-Leu-OH (2d): 
Synthesized according to the GP. Yield: 1.9 mg, 10%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (20, 65), (22, 98), (32, 98), tR = 10.573 min. – HPLC (analytical, S1): tR = 11.831 
min (DAD), Purity: 97%. – LC/MS (ESI, tR = 11.969 min): m/z (%) = 390.7 (40) [M+2H]2+, 780.3 (100) 
[MH]+. – HR-MS: [M+2H]2+ calcd. for C34H54BrN9O7 390.6738, found 390.6740. – MF: C34H54BrN9O7. – 
MW: 780.75.  
H-Lys-Arg-Pro-(αS,βR)-TAA-Leu-OH (2e): 
Synthesized according to the GP. Yield: 5.4 mg, 27%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (20, 65), (22, 98), (32, 98), tR = 10.883 min. – HPLC (analytical, S1): tR = 12.118 
min (DAD), Purity: 97%. – LC/MS (ESI, tR = 12.302 min): m/z (%) = 390.7 (45) [M+2H]2+, 780.3 (100) 
[MH]+. – HR-MS: [M+2H]2+ calcd. for C34H54BrN9O7 390.6738, found 390.6739. – MF: C34H54BrN9O7. – 
MW: 780.75.  
H-Lys-Arg-Pro-(αR,βS)-TAA-Leu-OH (2f): 
Synthesized according to the GP. Yield: 3.6 mg, 18%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (20, 65), (22, 98), (32, 98), tR = 10.561 min. – HPLC (analytical, S1): tR = 11.863 
min (DAD), Purity: 99%. – LC/MS (ESI, tR = 12.009 min): m/z (%) = 390.7 (55) [M+2H]2+, 780.3 (100) 
[MH]+. – HR-MS: [M+2H]2+ calcd. for C34H54BrN9O7 390.6738, found 390.6747. – MF: C34H54BrN9O7. – 
MW: 780.75.  
H-Lys-Lys-Pro-(αS,βR)-TAA-Leu-OH (2g): 
Synthesized according to the GP. Yield: 2.7 mg, 14%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (20, 65), (22, 98), (32, 98), tR = 10.615 min. – HPLC (analytical, S1): tR = 11.951 
min (DAD), Purity: 82%. – LC/MS (ESI, tR = 12.103 min): m/z (%) = 376.7 (40) [M+2H]2+, 752.3 (100) 
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[MH]+. – HR-MS: [M+2H]2+ calcd. for C34H54BrN7O7 376.6707, found 376.6712. – MF: C34H54BrN7O7. – 
MW: 752.74.  
H-Lys-Lys-Pro-(αR,βS)-TAA-Leu-OH (2h): 
Synthesized according to the GP. Yield: 2.5 mg, 13%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (20, 65), (22, 98), (32, 98), tR = 10.293 min. –  HPLC (analytical, S1): tR = 11.678 
min (DAD), Purity: 99%. – LC/MS (ESI, tR = 11.813 min): m/z (%) = 376.7 (50) [M+2H]2+, 752.3 (100) 
[MH]+. – HR-MS: [M+2H]2+ calcd. for C34H54BrN7O7 376.6707, found 376.6707. – MF: C34H54BrN7O7. – 
MW: 752.74.  
H-Arg-Arg-Pro-(αS,βR)-TAA-Ile-Leu-OH (3a)/H-Arg-Arg-Pro-(αR,βS)-TAA-Ile-Leu-OH (3b) – (3ab): 
Synthesized according to the GP. Yield: 11.1 mg, 24%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (10, 35), (13, 98), (23, 98), tR = 8.940 min. – HPLC (analytical, S1): tR = 12.841 min 
(DAD), Purity: 99%, Ratio 3a/3b: n.d. – LC/MS (ESI, tR = 12.967 min): m/z (%) = 461.2 (75) 
[M+2H]2+, 921.4 (100) [MH]+. – HR-MS: [M+2H]2+ calcd. for C40H65BrN12O8 461.2189, found 461.2192. 
– MF: C40H65BrN12O8. – MW: 921.92.  
H-Arg-Lys-Pro-(αS,βR)-TAA-Ile-Leu-OH (3c)/H-Arg-Lys-Pro-(αR,βS)-TAA-Ile-Leu-OH (3d) – (3cd): 
Synthesized according to the GP. Yield: 13.8 mg, 31%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (22, 71), (24, 98), (34, 98), tR = 8.897 min. – HPLC (analytical, S1): tR = 12.814 min 
(3c) / 12.714 min (3d) (DAD), Purity: 97%, Ratio 3c/3d: 72/25. – LC/MS (ESI, tR = 12.948 min / 
12.830 min): m/z (%) = 447.2 (80) [M+2H]2+, 893.4 (100) [MH]+. – HR-MS: [M+2H]2+ calcd. for 
C40H65BrN10O8 447.2158, found 447.2164. – MF: C40H65BrN10O8. – MW: 893.90.  
H-Lys-Arg-Pro-(αS,βR)-TAA-Ile-Leu-OH (3e)/H-Lys-Arg-Pro-(αR,βS)-TAA-Ile-Leu-OH (3f) – (3ef): 
Synthesized according to the GP. Yield: 18.5 mg, 41%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (10, 35), (13, 98), (23, 98), tR = 8.978 min. – HPLC (analytical, S1): tR = 12.703 min  
(DAD),  Purity: 99%, Ratio 3e/3f: n.d. – LC/MS (ESI, tR = 12.830 min): m/z (%) = 447.3 (50) 
[M+2H]2+, 893.4 (100) [MH]+. – HR-MS: [M+2H]2+ calcd. for C40H65BrN10O8 447.2158, found 447.2161. 
– MF: C40H65BrN10O8. – MW: 893.90.  
H-Lys-Lys-Pro-(αS,βR)-TAA-Ile-Leu-OH (3g)/H-Lys-Lys-Pro-(αR,βS)-TAA-Ile-Leu-OH (3h) – (3gh): 
Synthesized according to the GP. Yield: 8.2 mg, 19%; Purification by preparative HPLC. Gradient (t 
[min], % B): (0, 5), (22, 71), (24, 98), (34, 98), tR = 8.660 min. – HPLC (analytical, S1): tR = 12.614 min 
(3g) / 12.466 min (3h) (DAD), Purity: 97%, Ratio 3g/3h: 66/31. – LC/MS (ESI, tR = 12.765 min / 
12.602 min): m/z (%) = 433.3 (55) [M+2H]2+, 865.4 (100) [MH]+. – HR-MS: [M+2H]2+ calcd. for 
C40H65BrN8O8 433.2127, found 433.2133. – MF: C40H65BrN8O8. – MW: 865.90.  
H-Lys-Lys-Pro-(S)-Phe(4-Br)-Ile-Leu-OH (4a): 
Synthesized according to the GP. Yield: 36.0 mg, 87%; Purification by automated flash column 
chromatography (12g KP-C18-HS). Solvents: MeCN (B) / H2O (0.05% TFA (v,v)) (A); Flow rate: 12.0 
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mL/min. Gradient: linear from 3% B to 97% B within 35 min; UV detection at 220 nm. – HPLC 
(analytical, S2): tR = 12.513 min (DAD), tR = 12.600 min (ELSD), Purity: 92%. – LC/MS (ESI, tR = 1217-
1.289 min): m/z (%) = 275.8 (30) [M+3H]3+, 413.2 (100) [M+2H]2+, 825.4 (5) [MH]+. – HR-MS: 
[M+2H]2+ calcd. for C38H63BrN8O7 412.2074, found 412.2080. – MF: C38H63BrN8O7. – MW: 823.86.  
H-Lys-Lys-Pro-(R)-Phe(4-Br)-Ile-Leu-OH (4b): 
Synthesized according to the GP. Yield: 21.1 mg, 51%; Purification by automated flash column 
chromatography (12g KP-C18-HS). Solvents: MeCN (B) / H2O (0.05% TFA (v,v)) (A); Flow rate: 12.0 
mL/min. Gradient: linear from 3% B to 97% B within 35 min; UV detection at 220 nm. – HPLC 
(analytical, S2): tR = 13.371 min (DAD), tR = 13.464 min (ELSD) Purity: 86%. – LC/MS (ESI, tR = 1.382-
1.449 min): m/z (%) = 275.8 (60) [M+3H]3+, 413.2 (100) [M+2H]2+, 825.4 (5) [MH]+. – HR-MS: 
[M+2H]2+ calcd. for C38H63BrN8O7 412.2074, found 412.2083. – MF: C38H63BrN8O7. – MW: 823.86.  
 
3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-(4-bromophenyl)tetrahydrofuran-3-carboxylic 
acid (5): 
HCl*H-TAA-OH 1 (4.93 g, 15.3 mmol) was dissolved in a mixture of 40 mL aqueous Na2CO3 solution 
(10% w/w) and 20 mL of dioxane and cooled to 0 °C in an ice bath. Then a solution of Fmoc-Cl (3.96 
g, 15.3 mmol, 1 eq.) in 30 mL of dioxane was added drop wise over 30 min. The reaction mixture was 
stirred for 2 h at RT. Then the reaction mixture was poured on 400 mL of water and extracted twice 
with 80 mL of Et2O. The aqueous layer was cooled again to 0 °C and acidified with concentrated HCl 
to congo red paper. The white precipitate was extracted three times with 100 mL of EtOAc, the 
combined extracts were washed with water (50 mL), brine (50 mL) and dried over MgSO4. The 
solvent was removed under reduced pressure to receive the crude product as viscous yellow oil. The 
purification was done by automated flash column chromatography on silica gel applying a linear 
gradient of 22 % EtOAc / PE to 66% EtOAc / PE within 60 min and a flow rate of 50 mL min-1. The 
product was obtained as colorless solid with a yield of 51% (3.96 g, 7.8 mmol). 
Rf (EtOAc/PE = 3:1) = 0.18. – Mp: 166.1 °C. – 1H-NMR 
(600 MHz, COSY, DMSO-d6): δ = 2 21 (dd, 3JH,H = 4.4 Hz, 3JH,H 
= 12.0 Hz, 1H, 14a), 2.70 (dd, 3JH,H = 9.8 Hz, 3JH,H = 21.2 Hz, 
1H, 14b), 3.80 (dd, 3JH,H = 8.1 Hz, 3JH,H = 15.9 Hz, 1H, 15a), 
4.23 (pt, 3JH,H = 6.6Hz, 2H, 15b, 7), 4.33 (dt, 3JH,H = 10.3 Hz, 
3JH,H = 16.9 Hz, 2H, 6), 5.00 (bs, 1H, 16), 7.25 (d, 3JH,H = 8.4 
Hz, 2H, 18), 7.33 (q, 3JH,H = 7.2 Hz, 2H, 11), 7.41 (dd, 3JH,H = 
7.2 Hz, 3JH,H = 11.7 Hz, 2H, 10), 7.48 (d, 3JH,H = 8.4 Hz, 2H, 
19), 7.72 (dd, 3JH,H = 7.4 Hz, 3JH,H = 15.4 Hz, 2H, 9), 7.89 (d, 3JH,H = 7.1 Hz, 2H, 12), 8.07 (bs, 1H, 4), 12.29 
(bs, 1H, 1) – 13C-NMR (150 MHz, HSQC, HMBC, DMSO-d6): δ = 35 9 (-, 1C, 14), 47.2 (+, 1C, 7), 65.9 (-, 
1C, 6), 67.8 (-, 1C, 15), 70.8 (Cquat., 1C, 3), 85.4 (+, 1C, 16), 120.1 (Cquat., 1C, 17), 121.1 (+, 2C, 12), 125.3 
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(+, 2C, 9), 127.1 (+, 2C, 11), 127.6 (+, 2C, 10), 129.0 (+, 2C, 18), 130.5 (+, 2C, 19), 137.9 (Cquat., 1C, 20), 
141.2 (Cquat., 2C, 8), 144.1 (Cquat., 1C, 13), 144.4 (Cquat., 1C, 3), 155.9 (Cquat., 1C, 5), 171.8 (Cquat., 1C, 2) – 
MS (ESI, CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 508.0 (30) [MH]+, 549.0 (100) [MH+MeCN]+, 
1017.2 (25) [2MH]+, 1034.3 (25) [2MNH4]+ – HR-MS (PI-LSIMS, MeOH/CH2Cl2/NBA): calcd. for 
C26H22BrNO5 508.0754, 510.0738, found: 508.0755, 510.0736. – IR (neat) [cm-1]: ~ = 3404, 3281, 
3073, 2963, 2874, 2619, 1711, 1256, 1076, 1010, 736, 572, 528. – MF: C26H22BrNO5. – MW: 508.36.  
 
(2S,3S)-tert-Butyl-2-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-(4-bromophenyl)tetra-
hydrofuran-3-carboxamido)-3-methylpentanoate (6): 
Under an atmosphere of nitrogen Fmoc-TAA-OH 5 (500 mg, 0.987 mmol) was dissolved in 8 mL of 
dry DCM (8 mL/mmol) and cooled to 0 °C in an ice bath. To this solution DIPEA (421 µL, 2.459 mmol, 
2.5 eq.), HOBt (186 mg, 1.377 mmol, 1.4 eq.) and EDC*HCl (225 mg, 1.182 mmol, 1.2 eq) were added 
in this order. Afterwards the hydrochlorid salt of isoleucine tert-butyl ester (264 mg, 1.180 mmol, 1.2 
eq.) was slowly added in several portions. After the addition was completed, the mixture was allowed 
to reach room temperature and stirred for 24 hours. The reaction was quenched with 5 mL of water 
and acidified with 10 mL of 1M KHSO4 solution and extracted three times with 15 mL of DCM. The 
combined organic layers were washed with brine, dried over MgSO4 and the solvent was removed 
under reduced pressure. The purification was done by automated flash column chromatography on 
silica gel applying a linear gradient of 25 % Et2O / n-pentane to 60% Et2O / n-pentane within 45 min 
and a flow rate of 25 mL min-1. The product was obtained with a moderate yield of 41% (137 mg, 0.20 
mmol) for 6b respectively of 34% (115 mg, 0.17 mmol) for 6a. 
6a: colorless to slightly yellow solid – Rf (Et2O/n-pentane 
= 1:1) = 0.24. –Mp: 134.7 °C. –1H-NMR (600 MHz, COSY, 
CDCl3): δ = 0 81 (d, 3JH,H = 6.6 Hz, 3H, 19), 0.86-0.95 (m, 4 H, 
21+20a), 1.10-1.17 (m, 1H, 20b), 1.38-1.42 (m, 1H, 18), 1.46 
(s, 9H, 1), 2.37-2.48 (m, 1H, 22a), 2.92-3.00 (m, 1H, 22b), 
3.97-4.03 (m, 1H, 4), 4.23-4.27 (m, 1H, 11), 4.31-4.38 (m, 2H, 
23), 4.42-4.46 (m, 1H, 10), 4.53-4.58 (m, 1H, 10), 5.37 (bs, 
1H, 24), 6.57 (s, 1H, 8), 6.82 (d, 3JH,H = 6.4 Hz, 1H, 5), 7.21 (d, 
3JH,H = 7.9 Hz, 2H, 26), 7.31 (dd, 3JH,H = 6.8 Hz, 3JH,H = 13.8 Hz, 2H, 14), 7.38-7.42 (m, 4H, 15+27), 7.62 
(d, 3JH,H = 7.4 Hz, 2H, 13), 7.78 (t, 3JH,H = 6.3 Hz, 2H, 16). – 13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ = 
11.4 (+, 1C, 21), 14.9 (+, 1C, 19), 24.6 (-, 1C, 20), 28.1 (+, 1C, 1), 36.4 (-, 1C, 22), 37.9 (+, 1C, 18), 47.4 
(+, 1C, 11), 57.4 (+, 1C, 4), 66.4 (-, 1C, 23), 66.5 (-, 1C, 10), 67.2 (Cquat., 1C, 7), 79.1 (+, 1C, 24), 82.3 
(Cquat., 1C, 2), 120.1 (+, 1C, 16), 121.4 (Cquat., 1C, 28), 125.3 (+, 1C, 13), 126.8 (+, 1C, 26), 127.2 (+, 1C, 
14), 127.7 (+, 1C, 15), 131.4 (+, 1C, 27), 136.3 (Cquat., 1C, 25), 141.3 (Cquat., 1C, 17), 143.6 (Cquat., 1C, 12), 
154.4 (Cquat., 1C, 9), 170.5 (Cquat., 1C, 3), 171.0 (Cquat., 1C, 6). – MS (ESI, CH2Cl2/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 677.3 (100) [MH]+, 696.4 (40) [MNH4]+. – MF: C36H41BrN2O6. – MW: 677.62.  
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6b: colorless viscous oil – Rf (Et2O/n-pentane = 1:1) = 
0.31 – 1H-NMR (600 MHz, COSY, CDCl3): δ = 0 41 (d, 3JH,H = 
6.7 Hz, 3H, 19), 0.76 (t, 3JH,H = 6.8 Hz, 3H, 21), 0.78- 0.82 (m, 
1H, 20a), 1.04-1.09 (m, 1H, 20b), 1.36-1.40 (m, 1H, 18), 1.44 
(s, 9H, 1), 2.51 (dd, 3JH,H = 8.6 Hz, 3JH,H = 21.3 Hz, 1H, 22a), 
2.86-2.91 (m, 1H, 22b), 4.17 (dd, 3JH,H = 3.6 Hz, 3JH,H = 8.0 Hz, 
1H, 4), 4.24 (t, 3JH,H = 6.7 Hz, 1H, 11), 4.31-4.38 (m, 2H, 23), 
4.39-4.44 (m, 1H, 10), 4.49-4.55 (m, 1H, 10), 5.49 (bs, 1H, 
24), 6.43 (d, 3JH,H = 8.3 Hz, 1H, 5), 6.66 (s, 1H, 8), 7.21 (d, 3JH,H = 7.9 Hz, 2H, 26), 7.31 (dd, 3JH,H = 6.8 Hz, 
3JH,H = 13.8 Hz, 2H, 14), 7.38-7.42 (m, 4H, 15+27), 7.62 (d, 3JH,H = 7.4 Hz, 2H, 13), 7.78 (t, 3JH,H = 6.3 Hz, 
2H, 16). – 13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ = 11 5 (+, 1 , 21), 14 8 (+, 1 , 19), 24 8 (-, 1C, 
20), 28.0 (+, 1C, 1), 36.4 (-, 1C, 22), 37.8 (+, 1C, 18), 47.3 (+, 1C, 11), 57.3 (+, 1C, 4), 66.3 (-, 1C, 23), 
66.4 (-, 1C, 10), 67.0 (Cquat., 1C, 7), 79.2 (+, 1C, 24), 82.2 (Cquat., 1C, 2), 120.0 (+, 1C, 16), 121.4 (Cquat., 1C, 
28), 125.0 (+, 1C, 13), 126.7 (+, 1C, 26), 127.1 (+, 1C, 14), 127.8 (+, 1C, 15), 131.3 (+, 1C, 27), 136.2 
(Cquat., 1C, 25), 141.4 (Cquat., 1C, 17), 143.6 (Cquat., 1C, 12), 154.4 (Cquat., 1C, 9), 170.4 (Cquat., 1C, 3), 171.0 
(Cquat., 1C, 6). – MS (ESI, CH2Cl2/MeOH + 10 mmol/l NH4OAc): m/z (%) = 677.3 (100) [MH]+, 696.4 
(40) [MNH4]+. – MF: C36H41BrN2O6. – MW: 677.62. 
 
3.4.3  Biological investigations 
Receptor binding experiments. Receptor binding data were determined according to protocols as 
described previously.67,68 In detail, NTS1 binding was measured using homogenates of membranes 
from CHO cells stably expressing human NTS1 at a final concentration of 1-2 µg per well, and the 
radioligand [3H]neutrotensin (specific activity: 116 Ci mmol-1; PerkinElmer, Rodgau, Germany) at a 
concentration of 0.50 nM. Specific binding of the radioligand was determined at KD values of 0.37-
0.96 nM and a Bmax of 6170-9300 fmol(mg protein)-1. Nonspecific binding was determined in the 
presence of 10 µM neurotensin. NTS2 binding assays were carried out by the calcium phosphate 
method, using homogenates of membranes from HEK293 cells, which were transiently transfected 
with the pcDNA3.1 vector containing the human NTS2 gene (Missouri S&T cDNA Resource Center 
(UMR), Rolla, MO, USA).69 Membranes were incubated at a final concentration of 6-20 µg per well 
together with 0.50 nM [3H]NT(8-13) (specific activity: 136 Ci mmol-1); custom synthesis of [leucine-
3H]NT(8-13) by GE Healthcare, Freiburg, Germany) at KD values in the range of 0.67-2.02 nM and a 
Bmax value of 310-930 fmol(mg protein)-1. Nonspecific binding was determined in the presence of 
10µM NT(8-13), and the protein concentration was generally determined by the method of Lowry 
using bovine serum albumin as standard.70 
Data analysis. Data analysis of the competition curves from the radioligand binding experiments was 
accomplished by nonlinear regression analysis using the algorithms in Prism 5.0 (GraphPad Software, 
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San Diego, CA, USA). EC50 values derived from the resulting dose-response curves were transformed 
into the corresponding Ki values using the equation of Cheng and Prusoff.71 
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3.4.4  Supporting Information – Copies of selected NMR – spectra 
1H-NMR spectra of compound 5 (600 MHz, DMSO-d6): 
13C-NMR spectra of compound 5 (150 MHz, DMSO-d6):
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1H-NMR spectra of compound 6b (600 MHz, CDCl3):  
 
13C-NMR spectra of compound 6b (150 MHz, CDCl3): 
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4 Reduction of benzylic alcohols and α-hydroxycarbonyl compounds by 
hydriodic acid in a biphasic reaction medium 
 
The synthetic protocol for the reduction of alcohols to hydrocarbons by using hydriodic acid, first 
described by Kiliani more than 140 years ago, was improved to be more applicable to organic 
synthesis. Instead of a strongly acidic, aqueous solution, a biphasic toluene–water reaction medium 
was used, which allowed the conversion of primary, secondary and tertiary benzylic alcohols, in good 
yields and short reaction times, into the corresponding hydrocarbons. Red phosphorous was used as 
the stoichiometric reducing agent. Keto, ester, amide or ether groups are tolerated, and catalytic 
amounts of hydriodic acid (0.1 eq.) in the presence of 0.7 eq. phosphorous are sufficient to achieve 
conversion. 
 
 
 
 
 
This chapter was written in collaboration with Josef Herrmann and published in the “Beilstein 
Journal of Organic  hemistry”: Dobmeier,    Herrmann,       Lenoir, D    önig, B  Beilstein Journal of 
Organic Chemistry 2012, 8, 330-336. Josef Herrmann and Michael Dobmeier contributed equally to 
the written part of this chapter. Table entries based on experiments performed by Michael Dobmeier 
are marked with *. The alcohols 1-(4-methoxyphenyl)-2-phenylpropan-1-ol, 2-methyl-1-(thiophen-3-
yl)propan-1-ol, 4-methyl-2-phenylpentan-2-ol, 3-methyl-1-phenylbutan-1-ol, (E)-6-methyl-1-
phenylhept-4-en-3-ol, (E)-1-phenylhex-4-en-3-ol, 6,6-dimethyl-2-phenylhept-4-yn-3-ol, and ethyl 3-
(4-chlorophenyl)-3-hydroxy-butanoate were synthesized by Josef Herrmann. The alcohols N-benzyl-
2-hydroxy-2-phenylacetamide and rac-1,2-diphenylethane-1,2-diol were synthesized by Michael 
Dobmeier. Radical capture experiments with TEMPO were performed by Josef Herrmann. The mass 
efficiency analysis was contributed by D. Lenoir.  
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4.1 Introduction 
The reduction of hydroxy groups is a typical and important step in the synthesis of complex natural 
products or drugs.1-4 Functional-group tolerance during this reduction step is essential since various 
other groups are usually present. A number of synthetic procedures have been developed, which 
allow selective reduction, but only a few one-step transformations are known, which use either 
titanium-(III)5-8 or different metal complexes.9-13 Most procedures require a sequence of steps, e.g., 
the conversion of hydroxy groups into a chloride or bromide substituent and subsequent catalytic 
reduction with H2/Pt or the conversion into a tosylate and reduction with LiAlH4. The most 
commonly applied method is the Barton–McCombie reaction,14 due to its versatility and its very high 
functional group tolerance.15-18 Although very general, the reaction has some drawbacks: The 
involved organotin hydrides are costly, highly toxic19-21 and often difficult to separate from the 
reaction products. Furthermore, secondary alcohols give best results, while others may react less 
efficiently. 
We have reinvestigated the long-known reduction of benzylic alcohols and α-hydroxycarbonyl 
compounds by hydriodic acid.22-32 First described by Kiliani more than 140 years ago for the 
reduction of gluconic acid to hydrocarbons,33,34 the method has been reported for a variety of 
alcohols, but typically proceeds in aqueous solution and requires an excess of HI or strong mineral 
acids such as phosphoric or sulfuric acid.35-37 
We describe a biphasic reaction medium consisting of toluene and aqueous hydriodic acid. The phase 
separation allows milder reaction conditions compared to the classic Kiliani protocol and is more 
applicable to organic synthesis. 
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4.2  Results and Discussion 
4.2.1  Deoxygenation of benzylic alcohols and α-hydroxycarbonyl compounds 
Initial investigations focused on simple benzylic alcohols (Table 1, entries 1–3), which were 
converted in high to quantitative yields into the corresponding alkanes. Carbonyl groups or amides in 
a benzylic position (Table 1, entries 4 and 6) and aromatic hydroxy groups (Table 2, entry 7) or 
aromatic ethers (Table 1, entry 5) were not affected. Moreover, heterocycles such as thiophene 
(Table 1, entry 7) were stable under these conditions whereas furans (Table 1, entry 8) were 
decomposed due to ring opening. Benzylic alcohols were converted in good to high yields to alkanes 
with increasing reactivity in the order primary (2 h) < secondary (0.5–1 h) < tertiary alcohol (15–30 
min); carbonyl groups and ethers were tolerated. Diethyl tartrate was converted into diethyl 
succinate under the reaction conditions given (Table 1, entry 12), but some of the material was lost 
due to ester hydrolysis. 
Table 2. Reduction of benzylic alcohols and α-hydroxycarbonyl compounds to the corresponding alkanes. 
 
Entry Alcohol Product[a] Time [h] Yield [%] 
1* 
  
2 70[b] 
2* 
  
0.5 96 
3* 
  
0.25 100 
4* 
  
1 80 
5 
  
0.5 92 
6* 
  
1 82 
7 
  
0.5 62[c] 
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8* 
 
decomposition 1 – 
9 
  
0.25 74[c] 
10 
  
0.5 49[c] 
11* 
  
0.5 78 
12* 
  
1.5 65 
[a] All products are known compounds described in the literature. The identities have been proven 
by proton NMR and mass analysis, which match the literature data. [b] The corresponding iodo 
compound was identified as a byproduct. [c] The corresponding elimination product was obtained 
as a byproduct. 
 
4.2.2  Deoxygenation of allylic and propargylic alcohols 
Allylic alcohols are completely consumed, but the corresponding alkenes could not be isolated as 
pure products (Table 2). Mixtures of eliminiation and deoxygenation products, in some cases also 
rearangement of the deoxygenated product into the more highly substitued, thermodynamically 
more stable alkene occurred. Propargylic alcohols (Table 2, entry 3 and 4) showed elimination or 
decomposed. In the case of flavin (Table 2, entry 6), three hydroxy groups were reduced and one was 
converted into an iodo substituent.  
Table 2. Alcohols showing incomplete or unselective reaction with hydriodic acid and red phosphorous.[a] 
Entry Alcohol Product Time [h] Yield [%] 
1 
 
mixtures of several products 1 – 
2 
 
mixtures of several products 1 – 
3* 
  
1 traces 
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4 
 
decomposition 1 – 
5* 
 
decomposition 1 – 
6* 
  
2 21 
7* 
 
no conversion 1 – 
[a] 3.0 eq. HIaq., 0.4 eq. Pred. 
 
4.2.3  Conversion of aliphatic alcohols without π-system in α-position 
Alcohols other than those that were benzylic or α to carbonyl groups were not converted into the 
corresponding alkanes, and the reaction stopped at the iodoalkanes (Table 3). The reactivity follows 
the order of primary < secondary < tertiary alcohols, as expected for an SN1 reaction. The reduction 
potential of the nonbenzylic iodoalkanes is not sufficient for reduction by hydriodic acid.  
Table 3. Alcohols yielding alkyl iodides with hydriodic acid and red phosphorous.[a] 
Entry Alcohol Product Time [h] Yield [%] 
1* 
  
8 98 
2* 
  
8 83[b] 
3   20 81
[c] 
[a] 3.0 eq. HIaq., 0.4 eq. Pred. [b] Single isomer. [c] Products were analyzed by gas chromatography; 
chlorobenzene was used as an internal standard. 
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4.2.4  Mechanism of the deoxygenation with hydriodic acid 
The mechanism of reduction by hydriodic acid consists of two steps (Scheme 1): The nucleophilic 
substitution of the hydroxy group by iodide and the subsequent reduction of the alkyl iodide by 
hydriodic acid. The iodine, generated in the second step, is recycled by reduction with red 
phosphorous regenerating hydriodic acid. 
 
Scheme 4. Mechanism of the alcohol reduction and recycling of iodine. 
The mechanistic details of the redox comproportionation of alkyl iodides and H–I have been strongly 
debated in the literature.38-40 However, the required benzylic or α-carbonyl position for the redox 
comproportionation indicates an intermediate with mesomeric stabilization due to the adjacent π-
system. In a trapping experiment, using HI without phosphorous, diphenylcarbinol as the substrate 
and TEMPO as a trapping agent for radical intermediates, the TEMPO adduct of diphenylcarbinol was 
detected by mass analysis (Scheme 2). 
 
Scheme 2. Radical capture experiment with diphenylcarbinol and TEMPO. 
This indicates a radical mechanism of the redox comproportionation. We suggest a stepwise 
reduction by single electron transfer (SET) accompanied by the oxidation of I− to I2. The iodine, 
generated in the second step, is recycled by reduction with red phosphorous, regenerating hydriodic 
acid. Admittedly, the above-mentioned TEMPO adduct could also be generated by nucleophilic 
substitution of the alkyl iodide with reduced TEMPO. At least this would be another proof for the first 
reaction step (Scheme 3).  
Moreover the carbenium ion intermediate of the nucleophilic substitution (SN1) in the first reaction 
step, gives a logical explanation for the reaction of aromatic hydroxy groups with HI (Table 2 entry 7). 
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In the case of a benzylic substrate, the positive charge is located in a p-orbital and can be stabilized by 
the mesomeric effect of the adjacent π-system. In contrast the positive charge of the carbenium ion 
intermediate of an aromatic substrate is located in the orthogonal sp2-hybrid orbital and cannot 
benefit from the π-system. Therefore aromatic hydroxy groups do not react with hydriodic acid.  
 
 
Scheme 3. Possible reaction pathways for the generation of the TEMPO adduct.  
 
4.2.5  Deoxygenation with catalytic amounts of hydriodic acid 
According to the redox equations of the reaction between iodine and red phosphorous, each mole of 
red phosphorous is able to reduce at least 1.5 mol of iodine: 
3 I2 + 2 P + 6 H2O     6 HI + 2 H3PO3 
5 I2 + 2 P + 8 H2O     10 HI + 2 H3PO4 
Catalytic amounts of hydriodic acid are therefore sufficient28 for the reduction of the hydroxy group 
(Table 4), when excess red phosphorous is added as a terminal reducing agent (Table 4, entry 1 and 
3-6). However, depending on the amount of added hydriodic acid, the elimination of water may occur 
as an alternative reaction pathway (Table 4, entry 2). A low concentration of HI favors the elimination 
of water, while higher HI concentrations lead to substitution and reduction products (Table 4, entry 
1). But for substrates without a methyl, methylene of methane group in α-position (Table 4, entry 4-
6), even low concentration of HI were sufficient for deoxygenation. In these cases dehydration could 
not take place as alternative reaction pathway.  
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Table 4. Reduction of alcohols with catalytic amounts of hydriodic acid. 
Entry Alcohol Product[a] Time [h] Yield [%] 
1 
  
0.25 74[a] 
2 
  
0.25 67[b] 
3 
  
0.5 82[a] 
4* 
 
 
0.5 92[b] 
5* 
  
0.25 98[b] 
6* 
  
0.5 74[b] 
[a] 0.6 eq. HIaq., 0.4 eq. Pred. [b] 0.1 eq. HIaq., 0.7 eq. Pred. 
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4.3  Conclusion 
Toluene and aqueous hydriodic acid are a suitable biphasic reaction mixture for the reduction of a 
range of benzylic alcohols. The two-phase system makes the Kiliani protocol more easily applicable to 
organic synthesis, as organic substrates and products dissolve in the organic phase and are separated 
from the mineral acids. The procedure allows the use of catalytic amounts of hydriodic acid and red 
phosphorous as the terminal reductant. In the case of alcohols having no activation by adjacent 
benzylic or carbonyl groups the reaction stops at the corresponding alkyl iodide. A quantitative mass-
efficiency analysis41 of the reaction in comparison to tosylation/LiAlH4, Ti(III)-mediated and Barton–
McCombie reduction revealed a better atom economy and mass efficiency. 
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4.4  Experimental Section 
4.4.1  General 
All reagents and solvents used were of analytical grade, purchased from commercial sources and 
used without further purification. Unless stated otherwise, purification and drying of the solvents 
used was performed according to accepted general procedures. All reactions were performed under 
an inert atmosphere of N2 by using standard Schlenk techniques, if not otherwise stated. TLC analyses 
were performed on silica-gel-coated alumina plates (F254 silica gel, layer thickness 0.2 mm). 
Visualization was achieved by UV light at 254 nm/366 nm or through staining with ninhydrin or 
vanillin solutions. For preparative column chromatography, silica gels (70–230 mesh and 230–400 
mesh) were used. For chromatography commercially available solvents of standard quality were 
used without further purification.  
 
4.4.2  Syntheses 
Representative experimental procedure: 
The alcohol (1 mmol, 1 eq.) is dissolved in 4 mL of toluene. Red phosphorus (0.4 mmol, 0.4 eq.), 
followed by concentrated hydriodic acid (57% w/w, 3.0 mmol, 3 eq.) is added and the reaction 
mixture is heated to 80 °C for the stated time, allowed to cool to RT and quenched with Na2S2O3 (10 
mL; 10% w/w) solution. The aqueous phase is extracted with dichloromethane (3 × 10 mL), the 
combined organic phases are dried over MgSO4 and filtered, and the solvent is removed. The crude 
product is purified by chromatography and spectroscopically characterized. 
For catalytic reactions of 1 mmol of the respective alcohol the following amounts of hydriodic acid 
and Pred were used: (a) 0.6 mmol HIaq./0.4 mmol Pred, (b) 0.1 mmol HIaq./0.7 mmol Pred. 
 
1-(4-Methoxyphenyl)-2-phenylpropan-1-ol (Table 1, entry 5): 
The reaction was carried out under a dry nitrogen atmosphere by using standard Schlenk techniques. 
1 mL of a solution of 4-bromo-1-methoxybenzene (0.62 mL, 5.0 mmol) in dry THF (10 mL) was added 
to Mg powder (0.12 g, 5.0 mmol). The Grignard reaction was initiated by the addition of iodine 
followed by sonication for several minutes. When the exothermic reaction started the rest of the 4-
bromo-1-methoxybenzene solution was added through a septum by syringe over 15 min. After the 
addition, the reaction solution was heated under reflux for 1 h to complete the reaction. The reaction 
solution was allowed to cool to RT before 2-phenylpropionaldehyde (0.60 mL, 4.5 mmol) was added 
dropwise. To complete the reaction the solution was again heated under reflux for 2 h. The reaction 
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was quenched by the addition of HCl (2 M, 5 mL). The aqueous phase was extracted with diethyl 
ether (2 × 5 mL). The combined organic phases were washed with saturated NaHCO3 (3 mL), H2O (2 × 
2.5 mL) and dried with MgSO4. The solvent was removed with a rotary evaporator. The crude product 
was purified by flash chromatography (petroleum ether/ethyl acetate 4:1, staining with vanillin 
solution gave a blue spot). 1-(4-Methoxyphenyl)-2-phenylpropan-1-ol was isolated as yellow oil in 
57% yield (0.62 g, 2.6 mmol). Analytical data were identical with literature.42 
 Rf (PE/EtOAc = 4:1) = 0.30. – 1H-NMR (300 MHz, CDCl3): δ = 1 34 (d, 3JH,H = 7.0 Hz, 3H, –CH3), 3.09 
(pq, 3JH,H = 6.9 Hz, 1H, –CH-Ph), 3.78 (s, 3H, –OCH3), 4.76 (d, 3JH,H = 6.1 Hz, 1H, –CH-OH), 6.74-6.85 (m, 
2H, –CH=C-OMe), 7.05-7.45 (m, 7H, –C6H4–/–C6H5). – MS (EI): m/z (%) = 137.1 (53) [M–C8H9]+, 224.1 
(2) [M–H2O]+, 242.1 (1) [M]+. – MF: C16H18O2. – MW: 242.31. 
 
N-Benzyl-2-hydroxy-2-phenylacetamide (Table 1, entry 6): 
The reaction was carried out under a dry nitrogen atmosphere by using standard Schlenk techniques. 
To a solution of rac-mandelic acid (2.00 g, 13.1 mmol) in 55 mL of dry THF first benzylamine (1.44 
mL, 13.1 mmol) was added followed by N-hydroxysuccinimide (1.66 g, 14.5 mmol, 1.1 eq.). The 
reaction mixture was cooled to 0 °C and a solution of N,N-dicyclohexylcarbodiimide (2.98 g, 14.5 
mmol, 1.1 eq.) in dry THF (20 mL) was added over 15 min. After stirring for additional 15 min at 0 °C, 
the cooling bath was removed, the reaction mixture allowed to warm up to RT and stirred overnight. 
After this time, the mixture was filtered and the dicyclohexylurea cake washed with THF (2 × 10 mL). 
The solvent was removed under reduced pressure, and the residue was dissolved in EtOAc (120 mL). 
The organic layer was washed with sat. aq. Na2CO3 (25 mL), H2O (25 mL), aq. HCl (1 M, 25 mL), H2O 
(25 mL), and brine (25 mL) and dried over MgSO4. The solvent was removed under reduced pressure 
and the crude product was purified by flash chromatography on silica gel eluting with PE/Et2O 4:1. N-
Benzyl-2-hydroxy-2-phenylacetamide was obtained as colorless solid in 75% yield (2.38 g, 9.9 
mmol). Analytical data were identical with literature.43 
 Rf (PE/Et2O = 4:1) = 0.20. – 1H-NMR (300 MHz, CDCl3): δ = 4 07 (d, 3JH,H = 2.8 Hz, 1H, –OH), 4.36 
(dd, 2JH,H = 2.8 Hz, 3JH,H = 5.9 Hz, 2H, –CH2-Ph), 4.99 (d, 3JH,H = 2.1 Hz, 1H, –CH-OH), 6.77 (s, 1H, –NH–), 
7.16 (dd, 4JH,H = 1.8 Hz, 3JH,H = 7 Hz, 2H, –Ph), 7.25-7.38 (m, 8H, –Ph). – 13C-NMR (75 MHz, CDCl3): δ = 
43.4, 74.2, 126.8, 127.6, 128.6, 128.7, 128.8, 137.7, 139.5, 172.4. – MS (ESI): m/z (%) = 242.1 (10) 
[MH]+, 283.1 (19) [MH+MeCN]+, 483.2 (100) [2MH]+. – MF: C15H15NO2. – MW: 241.29. 
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rac-1,2-Diphenylethane-1,2-diol (Table 1, entry 11): 
To a solution of K3[Fe(CN)6] (19.75g, 60 mmol, 3 eq.) in 100 mL of H2O and 100 mL of tBuOH, K2CO3 
(8.29 g, 60 mmol, 3 eq.), trans-stilbene (3.60 g, 20 mmol) and K2[OsO4] x 2H2O (15 mg, 0.04 mmol, 
0.002 eq.) were added in this order. The reaction was stirred at RT for 48 hours. Afterwards Na2SO3 
(15.1 g, 120 mmol) were added and the reaction was stirred for additional 30 min. The phases were 
separated and the aqueous phase was extracted with EtOAc (3 x 30 mL). The combined organic 
phases were dried over MgSO4 and the solvent was removed under reduced pressure. The crude 
product was purified by flash column chromatography (PE/EtOAc 4:1). Rac-1,2-diphenylethane was 
isolated as colorless to slightly yellow solid in 57% yield (2.44 g, 11.4 mmol). Analytical data were 
identical with literature.44 
 Rf (PE/EtOAc = 4:1) = 0.28. – 1H-NMR (400 MHz, CDCl3): δ = 2 87 (bs, 2H, –OH), 4.74 (s, 2H, –CH-
OH), 7.12-7.29 (m, 10H, –Ph). – MS (EI): m/z (%) = 77.0 (100) [C6H5]+, 108.1 (71) [C7H8O]+, 214.3 
(38) [M]+. – MF: C14H14O2. – MW: 214.26. 
 
(E)-6-Methyl-1-phenylhept-4-en-3-ol (Table 2, entry 1): 
The reaction was carried out under dry nitrogen atmosphere by using standard Schlenk techniques. 
To a slurry of Mg powder (0.67 g, 28 mmol) in dry THF (4 mL), 2 mL of a solution of 2-phenyl-1-
bromethane (3.0 mL, 28 mmol) in dry THF (10 mL) was added. The Grignard reaction was initiated 
by the addition of iodine followed by sonication for several minutes. When the exothermic reaction 
started the rest of the 2-phenyl-1-bromethane solution was added through a septum by syringe over 
15 min. After the addition, the reaction solution was heated under reflux for 1 h to complete the 
reaction. The reaction solution was allowed to cool to RT before 4-methyl-2-pentenal (2.3 mL, 20 
mmol) was added dropwise. To complete the reaction the solution was again heated under reflux for 
1 h. The reaction was quenched by the addition of HCl (2 M, 25 mL). The aqueous phase was 
extracted with diethyl ether (3 × 15 mL). The combined organic phases were washed with saturated 
NaHCO3 (15 mL) and H2O (2 × 10 mL), and dried with MgSO4. The solvent was removed with a rotary 
evaporator. The crude product was purified by flash chromatography (petroleum ether/ethyl acetate 
4:1, staining with vanillin solution gave a blue spot). (E)-6-Methyl-1-phenylhept-4-en-3-ol was 
isolated as yellow oil in 74% yield (3.05 g, 14.9 mmol). 
 Rf (PE/EtOAc = 4:1) = 0.32. – 1H-NMR (300 MHz, CDCl3): δ = 1.00 (d, 3JH,H = 6.8 Hz, 6H, –CH3), 1.46 
(d, 3JH,H = 1.8 Hz, 1H, –OH), 1.72-1.97 (m, 2H, –CH2-CHOH–), 2.21-2.39 (m, 1H, –CH-(CH3)2), 2.59-2.79 
(m, 2H, –CH2-Ph), 4.01-4.13 (m, 1H, –CHOH–), 5.44 (ddd, 4JH,H = 1.2 Hz, 3JH,H = 7.0 Hz, 3JH,H = 15.5 Hz, 
1H, –CH=CH–), 5.63 (ddd, 4JH,H = 0.7 Hz, 3JH,H = 6.4 Hz, 3JH,H = 15.5 Hz, 1H, –CH=CH–), 7.14-7.33 (m, 5H, 
–C6H5). – 13C-NMR (75 MHz, CDCl3): δ = 21.3, 22.4, 30.7, 31.8, 38.8, 72.6, 125.8, 128.4, 128.5, 129.7, 
139.6. – MS (EI): m/z (%) = 91.1 (100) [C7H7]+, 161.1 (81) [M–C3H7]+, 186.1 (5) [M–H2O]+, 204.2 [M]+. 
– HR-MS: [M]+ calcd. for C14H20O 204.1514, found 204.1511. – MF: C14H20O. – MW: 204.31. 
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(E)-1-Phenylhex-4-en-3-ol (Table 2, entry 2): 
The reaction was carried out under a dry nitrogen atmosphere by using standard Schlenk techniques. 
A solution (1 mL) of 2-phenyl-1-bromethane (1.35 mL, 10.0 mmol) in dry THF (10 mL) was added to 
Mg powder (0.25 g, 10 mmol). The Grignard reaction was initiated by the addition of iodine followed 
by sonication for several minutes. When the exothermic reaction started the rest of the 2-phenyl-1-
bromethane solution was added through a septum by syringe over 15 min. After the addition, the 
reaction solution was heated under reflux for 1 h to complete the reaction. The reaction solution was 
allowed to cool to RT before crotonaldehyde (0.74 mL, 9.0 mmol) was added dropwise. To complete 
the reaction the solution was again heated under reflux for 2.5 h. The reaction was quenched by the 
addition of HCl (2 M, 10 mL). The aqueous phase was extracted with diethyl ether (2 × 15 mL). The 
combined organic phases were washed with saturated NaHCO3 (5 mL), H2O (2 × 5 mL) and dried with 
MgSO4. The solvent was removed with a rotary evaporator. (E)-1-Phenylhex-4-en-3-ol was obtained 
in 96% yield (1.53 g, 8.69 mmol) in analytical purity. Analytical data were identical with the 
literature.45 
 1H-NMR (300 MHz, CDCl3): δ = 1.46 (d, 3JH,H = 1.8 Hz, 1H, –OH), 1.67 (dd, 4JH,H = 0.7 Hz, 3JH,H = 6.3 
Hz, 3H, –CH3), 1.72-1.97 (m, 2H, –CH2-CHOH–), 2.56-2.73 (m, 2H, –CH2-Ph ), 4.02 (pq, 3JH,H = 6.7 Hz, 
1H, –CHOH–), 5.48 (ddd, 4JH,H = 1.4 Hz, 3JH,H = 7.0 Hz, 3JH,H = 15.3 Hz, 1H, –CH=CH–), 5.63 (dq, 3JH,H = 6.2 
Hz, 3JH,H = 15.3 Hz, 1H, –CH=CH–), 7.06-7.34 (m, 5H, –C6H5). – MS (EI): m/z (%) = 71.1 (100) [C4H7O]+, 
91.1 (67) [C7H7]+, 105.1 (19) [M–C4H7O]+, 176.1 (50) [M]+. – MF: C12H16O. – MW: 176.25. 
 
6,6-Dimethyl-2-phenylhept-4-yn-3-ol (Table 2, entry 4):  
The reaction was carried out under a dry nitrogen atmosphere by using standard Schlenk techniques. 
The solution of 3,3-dimethyl-1-butyne (0.62 mL, 5 mmol) in dry THF (10 mL) was cooled to −78 °   n-
BuLi (1.6 M in hexane, 3.5 mL, 5.6 mmol) was added dropwise through a septum by syringe. The 
reaction mixture was allowed to warm to RT before the solution of 2-propionaldehyde (0.68 mL, 5 
mmol) in dry THF (5 mL) was added dropwise through a septum by syringe. This solution was stirred 
for 4.5 h. The reaction was stopped by the addition of H2O (10 mL). The aqueous phase was extracted 
with diethyl ether (3 × 15 mL), and the combined organic layers were dried with MgSO4. The solvent 
was removed with a rotary evaporator. The crude product was purified by flash chromatography 
(petroleum ether/ethyl acetate 4:1, staining with vanillin solution gave a blue spot). 6,6-dimethyl-2-
phenylhept-4-yn-3-ol was isolated as colorless oil in 46% yield (0.50 g, 2.3 mmol).  
 Rf (PE/EtOAc = 4:1) = 0.42. – 1H-NMR (300 MHz, CDCl3): δ = 1.17 (s, 9H, –C(CH3)3), 1.39 (d, 3JH,H = 
7.1 Hz, 3H, –CH-CH3), 1.64 (d, 3JH,H = 7.4 Hz, 1H, –OH), 3.03 (dd, 3JH,H = 5.4 Hz, 3JH,H = 7.4 Hz, 1H, –CH-
Ph), 4.44 (dd, 3JH,H = 5.4 Hz, 3JH,H = 7.4 Hz, 1H, –CH-OH), 7.19-7.40 (m, 5H, –C6H5). – 13C-NMR (75 MHz, 
CDCl3): δ = 16.3, 30.0, 31.0, 46.1, 55.0, 67.5, 67.8, 78.1, 95.5, 127.0, 128.2, 128.8, 141.9. – MS (EI): m/z 
(%) = 57.1 (36) [C4H9]+, 99.1 (100), 105.1 (20) [C8H10]+, 216.2 (7) [M]+. – MF: C15H20O. – MW: 216.32. 
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4.4.3  Supporting Information – Mass efficiency analysis of alternative alcohol deoxygenation 
methods 
To allow a more quantitative comparison of the reduction method described herein with regard to 
environmental aspects and efficiency we determined the E factor which is defined in equation 1 of 
four alternative reactions for the synthetic step: HIaq./Pred (Scheme 4), tosylation/LiAlH4 (Scheme 5), 
Ti(III)-mediated (Scheme 6) and Barton-McCombie reduction (Scheme 7) 
    
          
            
  Equation 1 
 
 
Scheme 4. Reduction of an alcohol by phosphorous (analogously to Table 1, entry 2). 
 
 
Scheme 5. Lithium aluminium hydride as reducing agent for alcohols.46,47 
 
 
Scheme 6. Ti(III)-mediated reduction of alcohols.5 
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i)  
 
ii) 
 
iii) 
 
iv) 
 
Scheme 7. Tributyl stannane as reducing agent in a synthesis sequence (i–iv) resulting in cholest-5-ene.14 
The protocols were entered into the software EATOS41 in order to determine the waste per kilogram 
of product. The result is shown in Table 5 and in Figure 1. Software-assisted mass balance is a tool to 
identify issues that require optimization.48 
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i)  ii)  
Figure 1. Environmental factor (E) of the deoxygenation methodologies shown in Schemes 4 to 7 numbered 
consecutively with 1 to 4. Whereas i) only shows substances used during reaction, ii) also illustrates those being 
applied during work-up. As more substance amounts are used altogether (reaction + isolation in case of ii)), the 
scaling is different.  
Table 5. Reduction of alcohols with catalytic amounts of hydriodic acid. 
Entry 1 2 3 4 
i)     
Coupled products[a] 0.233 2.8862 2.4118 2.11 
By-products[a] 0.0514 2.4997 0.2284 0 
Substrates[a] 0 2.2933 1.3516 2.25 
Catalyst[a] 2.376 0 0 0 
Solvent[a] 16.4078 17.2271 23.7736 123 
Sewage/Water[a] 57.4502 14.8146 0 0 
ii)     
Coupled products[a] 0.233 2.8862 2.4118 2.11 
By-products[a] 0.0514 2.4997 0.2284 0 
Substrates[a] 0 2.2933 1.3516 2.25 
Catalyst[a] 2.376 0 0 0 
Solvent[a] 16.4078 17.2271 23.7736 123 
Aux. mat. (isolation) [a] 308.0334 1.8085 0 0 
Sewage/Water[a] 57.4502 14.8146 0 0 
     
Substrates[b] 1.2843 8.6793 4.9919 6.13 
     
Atom economy[c] 81 27 36 36 
[a] Values shown in Figure 1. [b] Substrate amounts that were used for the reaction. [c] Atom 
economies of the synthesis sequences shown in Scheme 4 to 7. 
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The hydriodic acid catalyzed reduction (entry 1 in Figure 1 (i) and Table 5) is, except for sewage 
production, the most mass-efficient reaction. The low amount of substrate demand (entry 1 in Table 
5[b]), which is due to the high atom economy (Table 5[c]), results in the formation of only low amounts 
of coupled products or byproducts compared to entries 2 to 4 (Figure 1 (i) and Table 5[a]). 
Additionally, some of the coupled products of entries 2 to 4 are supposed to be much more 
problematic with regard to waste treatment and recycling. In contrast, if hydriodic acid is not 
recycled it can easily be neutralized and disposed of in the sewage plant. The coupled product 
phosphoric acid will be easily flocculated in the treatment plant but will thereby contributing to the 
eutrophication problem. The catalytic use of iodine and the replacement of the stoichiometric reagent 
phosphorous, e.g., by an electrochemical method, are ways to improve the efficiency of the method. 
Another obvious optimization potential is the reduction of solvent and water during the work up. 
  
4 Reduction of benzylic alcohols and α-hydroxycarbonyl compounds by hydriodic acid in a biphasic 
reaction medium 
 
89 
4.5  References 
1. Larock, R. C., Ed. Comprehensive organic transformations: a guide to functional group 
preparations, 2nd ed.; Wiley-VCH: New York, 1999; pp 44-49. 
2. McCombie, S. W. In Comprehensive Organic Synthesis; Trost, B. M.; Fleming, I., Eds.; Pergamon 
Press: Oxford, U.K., 1991; Vol. 8, pp 811-833. 
3. Zard, S. Z. Xanthates and Related Derivatives as Radical Precursors. In Radicals in Organic 
Synthesis; Renaud, P.; Sibi, M. P., Eds.; Wiley-VCH: Weinheim, Germany, 2001; Vol. 1, pp 90-
108. 
4. ten Dam, J.; Hanefeld, U. ChemSusChem 2011, 4, 1017-1034. 
5. Diéguez, H. R.; López, A.; Domingo, V.; Arteaga, J. F.; Dobado, J. A.; Herrador, M. M.; Quílez del 
Moral, J. F.; Barrero, A. F. J. Am. Chem. Soc. 2010, 132, 254-259. 
6. Ledon, H.; Tkatchenko, I.; Young, D. Tetrahedron Lett. 1979, 20, 173-176. 
7. McMurry, J. E.; Silvestri, M. G.; Fleming, M. P.; Hoz, T.; Grayston, M. W. J. Org. Chem. 1978, 43, 
3249-3255. 
8. Sato, F.; Tomuro, Y.; Ishikawa, H.; Oikawa, T.; Sato, M. Chem. Lett. 1980, 9, 103-106. 
9. Corey, E. J.; Achiwa, K. J. J. Org. Chem. 1969, 34, 3667-3668. 
10. Crevier, T. J.; Mayer, J. M. J. Am. Chem. Soc. 1997, 119, 8485-8491. 
11. Lee, J.-T.; Alper, H. Tetrahedron Lett. 1990, 31, 4101-4104. 
12. Spiegel, D. A.; Wiberg, K. B.; Schacherer, L. N.; Medeiros, M. R.; Wood, J. L. J. Am. Chem. Soc. 
2005, 127, 12513-12515. 
13. Zhang, L.; Koreeda, M. J. Am. Chem. Soc. 2004, 126, 13190-13191. 
14. Barton, D. H. R.; McCombie, S. W. J. Chem. Soc., Perkin Trans. 1 1975, 16, 1574-1585. 
15. Barton, D. H. R.; Jang, D. O.; Jaszberenyi, J. C. Synlett 1991, 435-438. 
16. Barton, D. H. R.; Jang, D. O.; Jaszberenyi, J. C. J. Org. Chem. 1993, 58, 6838-6842. 
17. Barton, D. H. R.; Motherwell, W. B.; Stange, A. Synthesis 1981, 743-745. 
18. Zard, S. Z. Angew. Chem., Int. Ed. Engl. 1997, 36, 672-685. 
19. Appel, K. E. Drug. Metab. Rev. 2004, 36, 763-786. 
20. Boyer, I. J. Toxicology 1989, 55, 253-298. 
21. Dopp, E.; Hartmann, L. M.; Florea, A.-M.; Rettenmeier, A. W.; Hirner, A. V. Crit. Rev. Toxicol. 
2004, 34, 301-333. 
22. Aloy, J.; Rabaut, C. Bull. Soc. Chim. Fr. 1911, 9, 762-764. 
23. Aramini, A.; Sablone, M. R.; Bianchini, G.; Amore, A.; Fani, M.; Perrone, P.; Dolce, A.; Allegretti, M. 
Tetrahedron 2009, 65, 2015-2021. 
24. Dozeman, G. J.; Fiore, P. J.; Puls, T. P.; Walker, J. C. Org. Process Res. Dev. 1997, 1, 137-148. 
25. Gordon, P. E.; Fry, A. J. Tetrahedron Lett. 2001, 42, 831-833. 
26. Harvey, R. G.; Leyba, C.; Konieczny, M.; Fu, P. P.; Sukumaran, K. B. J. Org. Chem. 1978, 43, 3423-
3425. 
27. Hicks, L. D.; Han, J. K.; Fry, A. J. Tetrahedron Lett. 2000, 41, 7817-7820. 
4 Reduction of benzylic alcohols and α-hydroxycarbonyl compounds by hydriodic acid in a biphasic 
reaction medium 
 
90 
28. Marvel, C. S.; Hager, F. D.; Caudle, E. C. Org. Synth. 1923, 3, 45. 
29. Miescher, K.; Billeter, J. R. Helv. Chim. Acta 1939, 22, 601-610. 
30. Platt, K. L.; Oesch, F. J. Org. Chem. 1981, 46, 2601-2603. 
31. Shaw, K. N. F.; Armstrong, M. D.; McMillan, A. J. Org. Chem. 1956, 21, 1149-1151. 
32. Sugita, S. I.; Toda, S.; Yoshiyasu, T.; Teraji, T. Mol. Cryst. Liq. Cryst. 1993, 237, 399-406. 
33. Kiliani, H.; Kleemann, S. Ber. Dtsch. Chem. Ges. 1884, 17, 1296-1303. 
34. Perlin, A. S.; Purves, C. B. Can. J. Chem. 1953, 31, 227-236. 
35. Czaplicki, S.; Kostanecki, S. T. V.; Lampe, V. Ber. Dtsch. Chem. Ges. 1909, 42, 827-838. 
36. Milne, J. E.; Storz, T.; Colyer, J. T.; Thiel, O. R.; Dilmeghani Seran, M.; Larsen, R. D.; Murry, J. A. J. 
Org. Chem. 2011, 76, 9519-9524. 
37. Wu, G. G.; Chen, F. X.; LaFrance, D.; Liu, Z.; Greene, S. G.; Wong, Y. S.; Xie, J. Org. Lett. 2011, 13, 
5220-5223. 
38. Deno, N. C.; Friedman, N.; Hodge, J. D.; MacKay, F. P.; Saines, G. J. Am. Chem. Soc. 1962, 84, 4713-
4715. 
39. Gordon, P. E.; Fry, A. J.; Hicks, L. D. ARKIVOC 2005, vi, 393-400. 
40. Ogg, R. A., Jr. J. Am. Chem. Soc. 1934, 56, 526-536. 
41. Eissen, M.; Metzger, J. O. Chem. Eur. J. 2002, 8, 3580-3585. 
42. Zhou, C.; Wang, Z. Synthesis 2005, 1649-1655. 
43. Blay, G.; Fernández, I.; Marco-Aleixandre, A.; Pedro, J. R. Synthesis 2007, 3754-3757. 
44. Wang, Z.-M.; Sharpless, K. B. J. Org. Chem. 1994, 59, 8302-8303. 
45. Takahashi, M.; McLaughlin, M.; Micalizio, G. C. Angew. Chem. Int. Ed. 2009, 48, 3648-3652. 
46. Author collective Organikum: Organisch-chemisches Grundpraktikum, 16th ed.; VEB Deutscher 
Verlag der Wissenschaften: Berlin, 1986; p559. 
47. Schmid, H.; Karrer, P. Helv. Chim. Acta 1949, 32, 1371-1378. 
48. Eissen, M.; Weiß, M.; Brinkmann, T.; Steinigeweg, S. Chem. Eng. Technol. 2010, 33, 629-637. 
 
 5 Summary 
 
91 
5 Summary  
 
The first part of the thesis (chapter 1-3) describes the synthesis and use of tetrahydrofuran amino 
acids. In chapter 1 we summarize previous investigations followed by a more detailed description of 
the synthesis and conformational studies of the Cα-tetrasubstituted α-amino acid tert-butyl 2-(4-
bromophenyl)-3-((tert-butoxycarbonyl)amino)tetra-hydrofuran-3-carboxylate, which is of 
importance for the following chapters. 
Chapter 2 describes the synthesis of a small series of pyrene and carboxyfluorescein labeled 
unnatural tetrahydrofuran amino acid building blocks. They can be incorporated into peptides to 
rigidify the secondary structure and at the same time introducing a fluorescent label. The fluorescent 
dye can be coupled to the TAA before or after its incorporation into a peptide sequence using a 
Suzuki-type C-C bond formation on the bromoarene substituent, which illustrates the synthetic 
feasibility of these compounds. Thus these building blocks combine two properties which are often of 
high interest in the preparation of peptide analogues. The absorption and emission spectra of the 
prepared building blocks and peptides were investigated. Furthermore the fluorescence quantum 
yields of derivatives rac-3 and rac-6 were determined (ФF = 0 24±0 03 and ФF = 0.09±0.02, 
respectively). Compared to literature known values of pyrene (ФF = 0.58), the quantum yield is 
lower.. 
Chapter 3 reports the synthesis of a new class of NTS2 receptor selective ligands based on the 
structural modification of the lead structure NT(8-13) via solid phase supported peptide synthesis. 
The tetrahydrofuran amino acid HCl*H-TAA-OH was introduced as scaffold for Tyr11-Ile12 or Tyr11, 
respectively, leading to a small library of penta- and hexapeptides. For selected peptides that showed 
interesting biological activity when tested as mixtures of stereoisomers the crucial steps of an 
alternative synthetic pathway were investigated, allowing the synthesis of diastereomerically pure 
compounds. The biological investigations by radioligand binding assay at hNTS1 or hNTS2 receptors 
revealed that the prepared pentapeptides have only very low affinity and were therefore not further 
investigated. The Ki values for the hexapeptides showed good binding affinities and increased 
selectivity towards the NTS2 receptor. The most promising ligand possesses a Ki(NTS2) value of 67 ± 
12 nM and a selectivity ratio of 52 in favour of the NTS2 receptor. However, the most active and 
selective compound for the NTS2 receptor reported so far shows a smaller Ki(NTS2) of 2.8 ± 0.69 nM 
and a superior selectivity ratio of 22000. 
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The second part of this thesis (Chapter 4) deals with the reductive deoxygenation of alcohols. The 
method for the reduction of alcohols to hydrocarbons by using hydriodic acid and red phosphorous 
presented in Chapter 4, was described for the first time by Kiliani more than 140 years ago for the 
deoxygenation of gluconic acid. We improved this method, applying a biphasic toluene – aqueous 
hydriodic acid reaction medium. This allowed the separation of organic substrates, which dissolve in 
toluene, from the strongly acidic aqueous phase leading to milder reaction conditions and therefore 
being more applicable to organic synthesis. A range of primary, secondary and tertiary benzylic 
alcohols as well as α-hydroxycarbonyl compounds are converted in good yields and functional groups 
like keto, ester, amide, or ether groups are tolerated. With an access of red phosphorous as the 
stoichiometric reducing agent, catalytic amounts of hydriodic acid are sufficient to achieve full 
conversion. 
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6 Zusammenfassung 
 
Der erste Teil der vorliegenden Arbeit (Kapitel 1, 2 und 3) beschäftigt sich mit der Synthese und 
Anwendung von Tetrahydrofuran Aminosäuren. Kapitel 1 vermittelt dem Leser einen Überblick über 
die bisherigen Arbeiten auf diesem Gebiet. Eine detaillierte Beschreibung der Synthese und 
Konformationsuntersuchungen der Cα-tetrasubstituierten α-Aminosäure tert-butyl 2-(4-
bromophenyl)-3-((tert-butoxycarbonyl)amino)tetra-hydrofuran-3-carboxylat schließt die Einleitung 
ab. Diese Aminosäure wird in den folgenden Kapitel erneut genutzt. 
Kapitel 2 beschreibt die Synthese einer kleinen Serie unnatürlichen Tetrahydrofuran Aminosäuren-
Bausteine, welche mit Pyren oder Carboxyfluorescein-Einheiten fluoreszenzmarkiert wurden. Diese 
können, eingebaut in Peptide, deren Sekundärstruktur stabilisieren und gleichzeitig eine fluoreszente 
Markierung einfügen. Dabei kann der fluoreszierende Farbstoff durch eine Pd-katalysierte C-C-
Bindungsknüpfung am Bromoarene-Substituenten sowohl vor, als auch nach der Peptidsynthese an 
der Tetrahydrofuran Aminosäure eingeführt werden, welches die synthetischen Möglichkeiten dieser 
Verbindung aufzeigt. Damit vereinen diese Bausteine zwei Eigenschaften in Kombination, welche 
oftmals von besonderem Interesse in der Herstellung von Peptidmimetika sind. Die Absorptions- und 
Emissions-Eigenschaften der dargestellten Verbindungen wurden untersucht. Zusätzlich wurden die 
Fluoreszenzquantenausbeuten der Derivate rac-3 und rac-6 bestimmt (ФF = 0 24±0 03 bzw  ФF = 
0.09±0.02) und mit literaturbekannten Werten von Pyren (ФF = 0.58) verglichen, wobei sich eine 
deutlich niedrige Quantenausbeute zeigte. 
In Kapitel 3 wird über die Festphasenpeptidsynthese einer neuen Klasse von NTS2 
rezeptorselektiven Liganden berichtet, die auf einer einzelnen strukturellen Änderung der 
Leitstruktur NT(8-13) basieren. Die Tetrahydrofuran Aminosäure HCl*H-TAA-OH wurde dabei als 
Ersatz für Tyr11-Ile12 bzw. für Tyr11 eingebaut, wodurch eine kleine Bibliothek von Penta- und 
Hexapeptiden erhalten wurde. Um einen Zugang zu diastereomerenreinen Verbindungen zu haben, 
wurden für einige ausgewählte Peptide, welche in der biologischen Testung als Mischung von 
Stereoisomeren interessante Ergebnisse zeigten, die wesentlichen Schritte einer alternativen 
Syntheseroute untersucht. Die biologischen Untersuchungen mit Hilfe eines Bindungs-Assay unter 
Verwendung von radioaktivmarkierten Liganden an hNTS1 und hNTS2 Rezeptoren zeigten bei den 
Pentapeptiden nur geringe Aktivitäten, weshalb diese anschließend nicht weiter verfolgt wurden. Die 
Bindungskonstanten der Hexapeptide zeigten dagegen gute Bindungsaffinitäten und eine erhöhte 
Selektivität für den NTS2 Rezeptor. Verglichen mit dem aktivsten und selektivsten bekannten 
Liganden für diesen Rezeptor mit einem Ki(NTS2) = 2.8 ± 0.69 nM und einem Selektivitätsverhältnis 
von 22000, besitzt der beste TAA-Peptid Ligand nur einen Ki(NTS2) Wert von 67 ± 12 nM und ein 
Selektivitätsverhältnis von 52. 
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Der zweite Teil der Arbeit (Kapitel 4) beschäftigt sich mit der reduktiven Deoxygenierung von 
Alkoholen. Die in Kapitel 4 beschriebene Methode zur Reduktion von Alkoholen unter Verwendung 
von Iodwasserstoffsäure und rotem Phosphor wurde bereits vor mehr als 140 Jahren von Kiliani für 
die Deoxygenierung von Zuckersäuren, z.B. Gluconsäure beschrieben. Wir haben die Methode 
verbessert und ein zweiphasiges Reaktionsmedium aus Toluol und wässriger Iodwasserstoffsäure 
verwendet. Dadurch wird es ermöglicht, die in Toluol löslichen organischen Substrate von der stark 
sauren wässrigen Phase zu trennen und mildere Reaktionsbedingungen, welche sich besser zur 
organischen Synthese eigenen, einzustellen. Eine Reihe primärer, sekundärer und tertiärer 
benzylischer  lkohole sowie α-Hydroxycarbonyl-Verbindungen wurde in guten Ausbeuten unter 
Tolerierung von funktionellen Gruppen (Keto, Ester, Amide, und Ether) umgesetzt. Mit einem 
Überschuss an rotem Phosphor als stöchiometrisches Reduktionsmittel genügten katalytische 
Mengen an Iodwasserstoffsäure um vollständigen Umsatz zu erreichen. 
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°C  degree Celsius 
ε  molar extinction coefficients 
λ  Wavelength 
ФF  Fluorescence quantum yield 
µL  Micro liter 
µM  Micro molar 
13C-NMR  Carbon NMR 
1H-NMR  Proton NMR 
AA  Amino acid 
abs  absolute 
Ac2O  acetic anhydride 
Ala  Alanine 
Anal.  Elemental analysis 
APCI  atmospheric pressure chemical 
ionization 
aq.  aqueous 
Arg  Arginine 
Asn  Asparagine 
ATR  attenuated total reflectance 
Boc  t-butyloxycarbonyl 
calcd  calculated 
CDCl3  deuterated chloroform 
CHO  Chinese hamster ovary 
CI  chemical ionization 
Ci  Curie (1 Ci = 3.7*1010 Becquerel) 
CuI  Copper(I)-iodide 
Compd  compound 
COSY  correlated spectroscopy 
DAD  diode array detector 
DCC  N,N’-dicyclohexylcarbodiimide 
DCM  dichloromethane 
DEPT  distortionless enhancement by 
polarization transfer 
DIPEA  diisopropylethylamine 
DMAP  4-(dimethylamino)-pyridine 
DME  1,2-dimethoxyethan 
DMF  dimethylformamide 
DMSO  dimethylsulfoxide 
DMSO-d6  deuterated dimethylsulfoxide 
DVB  divinylbenzene 
EATOS  Environmental Assessment Tool 
for Organic Syntheses 
EC50  concentration of 50% observed 
effect 
EDC  1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide 
EI  electron impact ionization 
eq.  equivalent 
ESI  electrospray ionization 
Et2O  diethylether 
EtOAc  ethylacetate 
EtOH  ethanol 
eV  electron volts 
FAB  Fast atom bombardment 
FLD  fluorescence detector 
Fmoc  fluorenylmethoxycarbonyl 
FT  fourier transformed 
Glu  Glutamic acid 
Gly  Glycine 
GP  general procedure 
GPCRs  G-protein coupled receptors 
h  hour(s) 
H+  Proton 
HATU  2-(7-aza-1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HBTU  2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium 
hexafluorophosphate 
HCl  Hydrochloric acid 
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HEK293  human embryonic kidney 
HI  Hydriodic acid 
HMBC  heteronuclear multiple bond 
correlation 
HOAt  1-hydroxy-7-azabenzotriazole 
HOBt  1-hydroxybenzotriazole 
HPLC  High performance liquid 
chromatography  
HR  high resolution 
HSQC  heteronuclear single quantum 
coherence 
Hz  Hertz 
I  fluorescence intensity 
Ile  Isoleucine 
IR  Infrared spectroscopy 
J  coupling constant 
LC/MS  liquid chromatography/mass 
spectrometry 
Leu  Leucine 
LiAlH4  Lithium aluminium hydride 
LiOH  Lithium hydroxide 
Lys  Lysine 
K  Kelvin 
K2CO3  Potassium carbonate 
KHSO4  Potassium hydrogen sulfate 
KOH  Potassium hydroxide 
M  Molecule / Molar 
Me  methyl 
MeCN  acetonitrile 
MeOD  deuterated methanol, MeOH-d4 
MeOH  methanol 
Met  Methionine 
MF  molecular formula 
MgSO4  Magnesium sulfate 
MHz  Mega hertz 
min  minute(s) 
mL  Milli liter 
mm  Milli meter 
mmol  Milli mole 
Mp  melting point 
MS  mass spectrometry 
MW  molecular weight 
n  refractive index 
Na2CO3  Sodium carbonate 
NaHCO3  Sodium hydrogen carbonate 
Na2S2O3  Sodium thiosulfate 
Na2SO3  Sodium sulfite 
n.d.  not determined  
nm  Nano meter 
nM  Nano molar 
NMR  nuclear magnetic resonance 
NOE  nuclear overhauser effect 
NOESY  nuclear overhauser enhancement 
spectroscopy 
NT  Neurotensin 
(h)NTSx  (human) Neurotensin receptor 
subtype x (x = 1-3) 
Pbf  2,2,4,6,7-pentamethyldihydro-
benzofuran-5-sulfonyl 
Pd/C  Palladium on charcoal 
Pd(OAc)2  Palladium(II)-acetate 
Pd(PPh3)4  Tetrakis(triphenylphosphine)-
palladium(0) 
PE  petroleum ether  
  (hexanes, bp: 50-70 °C) 
PET  positron emission tomography 
pGlu  pyro Glutamic acid 
Ph  phenyl 
Phe  Phenylalanine 
PMT  Photo multiplier tube 
ppm  Parts per million 
Pred  Red phosphorous 
Pro  Proline 
Rf  Retention factor 
ROESY  rotating frame NOE spectroscopy 
RP  Reversed phase 
RT  room temperature 
sat.  Saturated 
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SD  standard deviation 
SEM  standard error of the mean 
SET  single electron transfer 
SPPS  solid phase (supported) peptide 
synthesis 
SR  selectivity ratio 
TAA  Cα-tetrasubstituted amino acid / 
Tetrahydrofuran amino acid 
TBAB  Tetrabuthylammoniumbromide 
TBDMS  tert-butyldimethylsilyl 
TBTU  O-(benzotriazole-1-yl)-N,N,N’,N’-
tetramethyluronium 
tetrafluoroborate 
tBu  tert.-butyl 
tBuOH  tert-butanol 
TEMPO  (2,2,6,6-tetramethyl-piperidin-1-
yl)-oxyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofurane 
TIS  triisopropylsilane 
TLC  thin layer chromatography 
TMS  tetramethylsilane 
tR  retention time 
Trp  Tryptophan 
TOF  time of flight 
Tyr  Tyrosine 
UV  ultraviolet / UV-Vis spectroscopy 
V  Volt 
Vis  visible 
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